

# Creating a New Standard for Addiction Treatment Outcomes

---

*A Report from the Institute for Behavior and Health, Inc.*

**Robert L. DuPont, MD, President**

**Institute for Behavior and Health, Inc.**

**6191 Executive Boulevard**

**Rockville, MD 20852 USA**

**[www.ibhinc.org](http://www.ibhinc.org)**

August 2014

## Table of Contents

Preface .....	2
IBH Addiction Treatment Outcomes Working Group .....	3
Introduction .....	4
Making Recovery the Expected Goal of Addiction Treatment .....	5
Perspective: Measuring Abstinence to Show Long-Term Recovery .....	6
The New Paradigm for Recovery .....	6
Physician Health Programs .....	6
Criminal Justice Programs .....	8
Implications for Five-Year Abstinence and Recovery Outcomes .....	9
Developing a New Framework for Long-Term Addiction Treatment Patient Outcomes .....	10
Approach #1: Standard Treatment Patient Outcome Assessment.....	11
Approach #2: Independent Outcome Assessment Focused on Patient Satisfaction.....	13
Approach #3: Recovery-Oriented System Model and Health Care Payers as Consumers .....	15
Summary .....	17
Conclusions and General Recommendations for Improving Long-Term Patient Outcomes.....	18
Appendix: Current Substance Use Disorder Treatment Efficacy Standards .....	20
A. Defining ‘Efficacy’ and Evidence-Based Treatment Practices (EBPs).....	20
B. Current EBP Classification Models and Approaches.....	21
C. Current Addiction Treatment Efficacy Measures .....	21
Behavioral Therapy .....	21
Pharmacological Therapy.....	22
D. Limitations of Current Efficacy Standards/Models.....	23
Tables .....	25
Table 1. Substance Use Disorder Treatment Models and Requirements to Determine Effectiveness .....	25
Table 2. Endpoints in the Treatment of Substance Use Disorders, by Substance .....	28

## Preface

On March 24, 2014, the Institute for Behavior and Health, Inc. (IBH) hosted a one-day symposium in Washington, DC of thought leaders with expertise in addiction treatment, research, health care, public policy, and government to discuss current outcome measures of treatment for substance use disorders and to recommend ways these measures could be improved. These individuals comprise the IBH Addiction Treatment Outcomes Working Group.

The symposium established a framework with a long-range perspective for the evaluation of addiction treatment. This framework recognized that addiction was a commonly chronic relapsing disorder and that follow-up monitoring and support *after treatment* was almost always absent, making relapse the expected outcome of addiction treatment. The new outcome evaluation framework aimed to make recovery the expected outcome of addiction treatment. Assessment of the success of addiction treatment would not be measured only, or even primarily, by what happens during treatment, as is common today, but rather by what would happen *after* treatment: “Then what?” would be the fundamental new question for treatment evaluation.

## **IBH Addiction Treatment Outcomes Working Group**

*Report Author and Working Group Chair:*

Robert L. DuPont, MD, President, Institute for Behavior and Health, Inc.

*Report Editor:*

Corinne L. Shea, MA, Director of Communications, Institute for Behavior and Health, Inc.

Members of the IBH Addiction Treatment Outcomes Working Group are listed in alphabetical order. An asterisk (\*) denotes participation in-person in the IBH symposium on the March 24, 2014. Points of view in this IBH Report are those of the Institute for Behavior and Health, Inc. and do not necessarily represent the views of members of the Working Group or member organizations.

John T. Carnevale, PhD\*, President and Chief Executive Officer, Carnevale Associates, LLC

Linda B. Cottler, PhD, MPH, Associate Dean for Research and Planning, College of Public Health and Health Professions; Dean's Professor and Chair, Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida

Monica Demitor\*, Chief Executive Officer, RiverMend Health, LLC

Amelia N. Deitchman, PharmD\*, PhD Candidate, Department of Pharmaceutics, University of Florida

Hartmut Derendorf, PhD\*, Distinguished Professor and Chair, Department of Pharmaceutics, College of Pharmacy, University of Florida

Helen DuPont, MBA\*, Executive Director, Institute for Behavior and Health, Inc.

William E. Ford, PhD\*, Chief Executive Officer, C4 Recovery Solutions, Inc.

Stuart Gitlow, MD, MPH, MBA\*, President, American Society of Addiction Medicine; Executive Director, Annenberg Physician Training Program in Addictive Disease

Mark S. Gold, MD\*, University of Florida Distinguished Professor; Donald R. Disney Eminent Scholar; University of Florida College of Medicine and McKnight Brain Institute

Erin Holmes, MA\*, Junior Fellow, University of Florida Drug Policy Institute

Cheryl D. Knepper, MA, LPC, ICCDP, ATR-BC, CSAT-S\*, Vice President of Continuum Services, Caron Treatment Centers

Carol McDaid\*, Co-Founder and Principal, Capitol Decisions, Inc.

A. Thomas McLellan, PhD, Chief Executive Officer, Treatment Research Institute

Charles P. O'Brien, MD, PhD\*, Kenneth Appel Professor, Department of Psychiatry, University of Pennsylvania

Kenneth W. Thompson, MD\*, Medical Director, Caron Treatment Centers

## Introduction

The United States has had a century of experience with independent clinicians and programs that deliver services to treat persons suffering from substance use disorders. For the most part these addiction treatment programs and clinicians operate in a specialized segment of medical care that lack standards of effectiveness and measures of long-term outcomes. Though substance use disorders are chronic illnesses, unlike the routine treatment for other chronic conditions such as diabetes or heart disease, there is no long-term or lifelong model of addiction treatment and few replicable standard measures of long-term treatment outcomes.

Presently, the typical measure of the effectiveness of substance use disorder treatment is reduction in the quantity or frequency of substance use during the course of a treatment intervention or, in rare instances, up to 12 months post-intervention. Such a short follow-up interval fails to reveal whether there are long-term benefits derived from a particular episode of treatment. A shift to long-term outcome measures of sustained recovery as opposed to short-term periods of reducing the use of one or more drugs has the potential to change the way in which treatment is evaluated. The data from such a long-term outcome evaluation has the potential to guide changes in treatment to improve long-term outcomes.

This report from the Institute for Behavior and Health, Inc. proposes a standard measure of five-year recovery for the treatment of substance use disorders. This long process of change begins by redefining the *initial* primary goal of addiction treatment as being both long-term abstinence from the use of alcohol and other drugs and improved quality of life. It also begins with identifying practical strategies for how long-term patient outcomes can be assessed. How can addiction treatment programs and clinicians that provide episodes of treatment for substance use disorders, insurance companies that cover the costs of this care, and others including employers and the criminal justice system assess long-term outcomes? Using sustained five-year abstinence and recovery as the primary measure of treatment outcomes can reshape both research and clinical practice. It can increase the quality of treatment, spawn a new generation of monitoring and care management and deliver more consistently the outcome widely sought but seldom achieved: a sustained addiction- and substance-free, healthy lifestyle.

The adoption of five-year abstinence and recovery as a treatment outcome measure would not replace other measures of effectiveness, including in-treatment assessments, but it would add to those measures. It would ensure that the standard measure of treatment effectiveness is long-term recovery and it would encourage addiction treatment programs and clinicians to make recovery the expected outcome of treatment. This report suggests a way forward to a standard of five years for assessing the outcomes of addiction treatment. It encourages providers and payers in addiction treatment to develop a variety of ways to assess five-year outcomes with the goal of improving treatment outcomes.

The report briefly reviews the definition of “recovery”, reviews the evidence that supports the proposition that long-term recovery can be the expected outcome of substance use disorder treatment, and discusses alternate methods that could be used to collect five-year abstinence and recovery

outcome data. An Appendix reviews the current measures of effectiveness and evidence-based treatment for substance use disorders.

## **Making Recovery the Expected Goal of Addiction Treatment**

Sustained recovery and an improved quality of life should be the expected goal of treatment for substance use disorders. A broadly representative group of experts convened by the Betty Ford Institute in 2007 defined recovery as “a voluntarily maintained lifestyle characterized by sobriety, personal health, and citizenship.”<sup>1</sup> The American Society of Addiction Medicine (ASAM) defined recovery as “a process of sustained action that addresses the biological, psychological, social, and spiritual disturbances inherent in addiction. This effort is in the direction of a consistent pursuit of abstinence, addressing impairment in behavioral control, dealing with cravings, recognizing problems in one’s behaviors and interpersonal relationships, and dealing more effectively with emotional responses. Recovery actions lead to reversal of negative, self-defeating internal processes and behaviors, allowing healing of relationships with self and others. The concepts of humility, acceptance, and surrender are useful in this process.”<sup>2</sup> The Substance Abuse and Mental Health Services Administration (SAMHSA) defines recovery from mental disorders and substance use disorders as, “a process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential.”<sup>3</sup>

Recovery implies long-term abstinence from the use of alcohol and other drugs. This report considers abstinence to be an immediate goal of treatment both during episodes of treatment and following discharge from treatment. The use of prescribed medicines, including buprenorphine, methadone and naltrexone, as intended by prescribing physicians is fully compatible with abstinence, but the nonmedical use of other drugs, including alcohol, is not. The gold standard for this model of abstinence used by programs featured in this report is also the standard of the 12-step fellowships of Alcoholics Anonymous and Narcotic Anonymous. Abstinence is not necessarily a primary objective of all addiction treatment programs. Some set a treatment goal, of cutting down on alcohol or other drug use or so called “responsible” or “safe” use of alcohol or other drugs. While there is evidence that a significant reduction in alcohol drinking is beneficial to health, total abstinence is the preferred and most stable outcome goal for treatment programs.

---

<sup>1</sup> Betty Ford Institute Consensus Panel. (2007). What is recovery? A working definition from the Betty Ford Institute. *Journal of Substance Abuse Treatment*, 33(3), 221-228.

<sup>2</sup> American Society of Addiction Medicine. (1982, February 1). State of Recovery. Public Policy Statement on the State of Recovery. Available: <http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2011/12/16/state-of-recovery>

<sup>3</sup> Substance Abuse and Mental Health Services Administration. (2011, December 22). SAMHSA announces a working definition of “recovery” from mental disorders and substance use disorders. *SAMHSA News Release*. Rockville, MD: SAMHSA. Available: <http://www.samhsa.gov/newsroom/advisories/1112223420.aspx>

Recovery also includes healthy living, wellness, and productive engagement.<sup>4</sup> Common measures of addiction treatment assess outcomes only during treatment and measure only the reduction in the use of a specific drug. This discrepancy is especially egregious because all episodes of addiction treatment are brief, while substance use disorders are life long, with a continuing threat of relapse. There is a popular perception that treatment ‘fixes’ those with substance use disorders. This perception fails to recognize the lifelong nature of the disorder. It has important public health policy implications because it limits the way that outcomes of treatment and other interventions are defined and measured, and encourages acceptance of limited outcomes.

### Perspective: Measuring Abstinence to Show Long-Term Recovery

Because abstinence is a realistic objective in addiction treatment and is a primary foundation for establishing recovery, this report places emphasis on measuring abstinence. The programs featured in this report measure abstinence with results from frequent, random drug and alcohol testing. Such results demonstrate that five-year abstinence is being achieved by individuals with substance use disorders.

As noted, in this report there is much more to recovery than abstinence. Only after an extended period of abstinence, improved state of personal health and engaged citizenship, can an individual be considered to be in recovery.

## The New Paradigm for Recovery

New systems of active, long-term care management – which may include episodes of relapse followed by return to addiction treatment – demonstrate that long-term abstinence and recovery can be the expected outcome of addiction treatment. Long-term abstinence is best exemplified by the system of care management used for the past four decades to treat addicted physicians, commercial pilots and lawyers. This model of long-term, active care management for substance use disorders, termed the New Paradigm, is comparable to the way treatments for other chronic conditions today are managed in medicine.<sup>5</sup>

**Physician health programs.** Physician health program (PHP) care management requires abstinence conditions (for alcohol and all non-prescribed drugs), intensive and sustained monitoring and deterrence through swift, certain, and meaningful consequences for non-compliance. The length of the PHP model of care management separates this model from other treatment interventions. Participating physicians

---

<sup>4</sup> Institute for Behavior and Health, Inc. (2014). The New Paradigm for Recovery: Making Recovery – and Not Relapse – the Expected Outcome of Addiction Treatment. A Report of the John P. McGovern Symposium, November 18, 2013, Washington, DC.

<sup>5</sup> Ibid.

are required to sign a five-year monitoring contract.<sup>6</sup> The PHP program typically begins with a formal episode of treatment, either residential or intensive outpatient day treatment, lasting between 30 to 90 days (with an average of 72 days). Following successful completion, participants are subject to intensive random substance testing throughout the duration of the program, although the frequency of testing tapers over time and as a result of sustained compliance. With random testing at any frequency, testing can occur on any day, even the day immediately following a test. This random testing is crucial to the effectiveness of the PHP care management and the New Paradigm. The long-term outcomes of the PHPs are consistent across primary substances of abuse (e.g. alcohol and intravenous use of opiates), and among physicians from different specialties (e.g. surgeons and anesthesiologists).

The long-term recovery rates for physicians in PHPs are between 70-96 percent which is the highest in all of the treatment outcome literature.<sup>7</sup> A longitudinal cohort study of 904 physicians admitted to 16 PHPs used outcome measures of program completion, continued abstinence of alcohol and other drug use, and continued occupation after five years.<sup>8</sup> Of the original sample, there were known outcomes for 802 physicians. Only 155 (19.3 percent) failed to complete their contract of treatment and supervision; over half of these individuals voluntarily stopping their medical licenses, another 30 percent had their medical licenses revoked, and others died either during monitoring or before five-year follow-up. Of the 647 (80.7 percent) physicians that completed treatment and resumed practice under supervision and monitoring, alcohol or drug use was detected by urine testing in only 126 (19 percent) over the five-year period with only 33 (26 percent) of these participants who had a test positive for alcohol or drug use having repeat positive test results. Approximately 81 percent of participants never failed a test for alcohol or any other drug during their five-year participation in the PHP. At the five-year follow-up, 78.7 percent of the participants were licensed to practice and still working. The remainder of participants were retired (3.5 percent), died (3.7 percent), or had an unknown status (3.2 percent). Only 10.8 percent had their licenses revoked.

The concern has been raised that the PHP results are atypical because they apply to a specific population that is well-educated and highly motivated to comply with program requirements and remain abstinent.<sup>9 10</sup> Physicians in PHPs are faced with the loss of their medical license (i.e., their

---

<sup>6</sup> DuPont R. L., McLellan A. T., White W. L., Merlo L., & Gold M. S. (2009). Setting the standard for recovery: Physicians Health Programs evaluation review. *Journal for Substance Abuse Treatment*, 36(2), 159-171.

<sup>7</sup> Ibid. [See: Domino, K. B., Hornbein, T. F., Polissar, N. L., Renner, G., Johnson, J., Alberti, S., & Hankes, L. (2005). Risk factors for relapse in health care professionals with substance use disorders. *JAMA*, 293, 1453-1460; Gastfried, D. R. (2005). Physician substance abuse and recovery: What does it mean for physicians—and everyone else? *JAMA*, 293, 1513-1515; Gold, M. S., & Aronson, M. D. (2004). *Treatment of Alcohol Abuse and Dependence*. Cambridge, MA: Harvard University UpToDate (CD ROM educational program); Smith, P. C., & Smith, J. D. (1991). Treatment outcomes of inpatient physicians in Oklahoma. *Journal of Oklahoma State Medical Association*, 84, 599-6-3; Talbott, G., & Wright, C. (1987). Chemical dependency in healthcare professionals. *Occupational Medicine*, 2, 581-591.]

<sup>8</sup> McLellan, A. T., Skipper, G. E., Campbell, M. G. & DuPont, R. L. (2008). Five-year outcomes in a cohort study of physicians treated for substance use disorders in the United States. *British Medical Journal*, 337:a2038.

<sup>9</sup> DuPont, R. L. & Humphreys, K. (2011). A new paradigm for long-term recovery. *Substance Abuse*, 32(1), 1-6.

<sup>10</sup> DuPont R. L., McLellan A. T., White W. L., Merlo L., and Gold M. S. (2009). Setting the standard for recovery: Physicians Health Programs evaluation review. *Journal for Substance Abuse Treatment*, 36(2), 159-171.



livelihood) and, as such, might be less resistant to behavior change; however, evidence from two criminal justice programs that have similar intensive monitoring procedures suggest that similar rates of long-term abstinence and improved quality of life can be achieved in criminal offender populations with substance use problems.

**Criminal justice programs.** Participants in Hawaii’s Opportunity Probation with Enforcement (HOPE) have significant documented substance use problems and are at high risk for violating probation. In HOPE, offenders are subject to frequent random drug and alcohol testing for up to five years. A missed test or a positive drug test is met with an immediate short-term jail stay. Formal addiction treatment is available to offenders who request it and to those who demonstrate the need for treatment by repeated non-compliance and relapse to drug use. A randomized controlled evaluation found that after one year in the program, compared to offenders on standard probation, HOPE participants were 72 percent less likely to use drugs and 55 percent less likely to be arrested for a new crime.<sup>11</sup>

South Dakota’s 24/7 Sobriety Project is a similar program that specifically focuses on repeat driving under the influence (DUI) offenders. Participants are subject to twice-daily alcohol breath tests or to wearing continuous alcohol monitoring ankle bracelets, and subject to random drug urinalysis or wearing drug patches to detect the use of illegal drugs. Any positive test results in an immediate short-term jail stay. Formal addiction treatment is available but optional. Over the course of an average 120 days in the program, 55 percent of participants never fail an alcohol test, 16.7 percent fail once, 12.5 percent fail only twice and 16.9 percent fail three or more.<sup>12</sup> DUI recidivism is substantially lower among 24/7 Sobriety participants at one, two and three years following program completion and repeat offenses have dropped 12 percent at the county level.<sup>13</sup>

Drug Courts serve high-risk, high-need criminal offenders with diagnosed substance use disorders who are eligible for community supervision such as probation.<sup>14</sup> Participants are supervised by multidisciplinary teams that develop individualized treatment plans. Participants attend regular judicial status hearings and are subject to frequent random drug testing and gradually escalating sanctions, including short jail stays, for infractions of supervision such as drug use or missed appointments. Because Drug Court participants are mandated to participate in formal addiction treatment offenders are retained in addiction treatment longer than in other correctional programs. The impact of Drug Courts is impressive, significantly reducing re-arrest rates and promoting abstinence from alcohol and

---

<sup>11</sup> Hawken, A., & Kleiman, M. (2009, December). Managing drug involved probationers with swift and certain sanctions: Evaluating Hawaii’s HOPE. National Institute of Justice, Office of Justice Programs, U.S. Department of Justice. Award number 2007-IJ-CX-0033.

<sup>12</sup> South Dakota 24/7 Sobriety Program. Presented by Art Mabry, 24/7 Sobriety Program Coordinator. Available: <http://apps.sd.gov/atg/dui247/247ppt.pdf> (Retrieved July 8, 2014)

<sup>13</sup> Kilmer, B., Nicosia, N., Heaton, P., & Midgette, G. (2013). Efficacy of frequent monitoring with swift, certain, and modest sanctions for violations: insights from South Dakota's 24/7 Sobriety Project. *American Journal of Public Health, 103*(1), e37-e43.

<sup>14</sup> National Association of Drug Court Professionals. (2013). *Adult Drug Court Best Practice Standards: Volume I*. Alexandria, VA: National Association of Drug Court Professionals. Available: <http://www.nadcp.org/sites/default/files/nadcp/AdultDrugCourtBestPracticeStandards.pdf>

drug use. With cessation of drug use, there comes the potential for the improved quality of life in true recovery.

**Implications for five-year abstinence and recovery outcomes.** The findings from the PHPs and from criminal justice system programs using similar long-term monitoring with consequences for any use of alcohol or other drugs are in stark contrast to typical outcomes for other programs. The latter programs show that a substantial percentage of participants (40-60 percent) relapse within six months of completing an episode of formal addiction treatment.<sup>15</sup> The promising evidence from the New Paradigm programs provides a benchmark against which other programs can measure attainment of long-term abstinence and recovery as a realistic standard for treatment outcome.

A hallmark of the New Paradigm of care management pioneered by the PHPs and other innovative programs is prolonged and intense monitoring through frequent random drug and alcohol testing to discourage and to identify substance use. A similar treatment parallel now occurs in medical practice. Recognizing that many chronic illnesses have significant behavioral elements and that compliance with good medical care is essential to manage chronic diseases, there is a new commitment to use of routine, sustained and long-term monitoring of patient behavior and compliance to improve outcomes. The commitment to patient-centered medical care with long-term monitoring and frequent assessment holds great promise for the management of substance use disorders. With such a model, health care clinicians could be encouraged to monitor patients with these disorders routinely regarding the status of their recovery. The successful management of substance use disorders includes conducting frequent random tests for the use of alcohol and other drugs as a routine monitoring of compliance, similar to the sustained monitoring for diabetes and hypertension. This model of integrated long-term monitoring and care management now being widely adopted throughout medicine holds the promise of incorporating many elements of the PHP model into routine health care for every patient suffering from a substance use disorder. In this context it is essential that health care clinicians not only recognize their important role in medically managing substance use disorders but that they also understand that long-term recovery is the objective. That means articulating this objective to patients and monitoring for its achievement. It also means that among health care there is must be a general recognition that the goal for patients with significant substance use disorders is complete abstinence from the use of alcohol and other drugs, and accompanying steps towards an improved quality of life.

---

<sup>15</sup> McLellan, A. T., Skipper, G. E., Campbell, M. G. & DuPont, R. L. (2008). Five-year outcomes in a cohort study of physicians treated for substance use disorders in the United States. *British Medical Journal*, 337:a2038. [See: Institute of Medicine (US) Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders. (2006). *Improving the quality of health care for mental and substance-use conditions*. Washington, DC: Institute of Medicine; Hubbard, R.L., Flynn, P.M., Craddock, G., & Fletcher, B. (2001). Relapse after drug treatment. New Haven, CT: Yale University Press; Project Match Research Group. (1997). Matching alcoholism treatments to client heterogeneity: project MATCH posttreatment drinking outcomes. *Journal of Studies on Alcohol*, 58(1), 7-29; Simpson, D. D., Joe, G. W., & Brown, B. S. (1997). Treatment retention and follow-up outcomes in the drug abuse treatment outcome study (DATOS). *Psychology of Addictive Behaviors*, 11(4), 294-301; Moos, R. H., Finney, J. W., & Cronkite, R. C. (1990). *Alcoholism treatment: context, process and outcome*. New York: Oxford Press.]

## Developing a New Framework for Long-Term Addiction Treatment Patient Outcomes

The Appendix at the end of this document provides a broad overview of some of the current standards for determining the effectiveness of substance use disorder treatment interventions. These current standards mainly focus on substance-specific outcomes of patients while in treatment, and in the short-term following discharge. It is not useful to eliminate the current welter of methods to assess the efficacy of specific substance use disorder treatment interventions. Instead, there is an opportunity to raise the relevance of assessment standards by adding the long-term perspective with a focus on sustained recovery.

As of 2014, with the implementation of the Affordable Care Act (ACA), services for substance use disorders must be included in all health insurance sold on Health Insurance Exchanges or provided by Medicaid. This will greatly increase access to addiction treatment for individuals who had previously been unable to afford these services. The Department of Health and Human Services (DHHS) is charged with the responsibility of identifying which evidence-based services will be insured. More specifically, DHHS “will take into account evidence on what services allow individuals to get the treatment they need and help them with recovery”.<sup>16</sup> Ideally, patients would have access to those services that have the strongest evidence-base as well as the best long-term outcomes for sustained recovery.

In addition to the impending increase in the number of individuals eligible for coverage of addiction treatment, in the current fiscal climate there is an intense focus on potential cost-saving strategies. With addiction treatment fewer instances of relapse and improved long-term outcomes in sustained recovery will lead to reductions in the costs associated with substance-related hospitalizations, impaired driving crashes, and incarceration. Research has shown that for every dollar spent on substance use disorder treatment, there is a return of \$4-7 in reduced theft, drug-related crime, and criminal justice costs; with healthcare in this equation, the savings are a ratio of 12:1.<sup>17</sup> It is important that insurance providers support treatment and care monitoring that improves their members’ health, reduces their future health care costs and most notably, reduces readmission for treatment of substance use disorders.

Cost-savings aside, when individuals with substance use disorders enter addiction treatment programs there is an expectation on the part of their families, employers, insurers and others that once patients complete the episode of care and are discharged, they will be securely on the road to long-term recovery. The new focus of treatment evaluation fits with this common expectation for the outcome of treatment even though it contrasts strikingly with the current performance of addiction treatment.

---

<sup>16</sup> Office of National Drug Control Policy. (n.d.). Substance abuse and the Affordable Care Act. Available: <http://www.whitehouse.gov/ondcp/healthcare>

<sup>17</sup> National Institute on Drug Abuse. (2012). *Principles of Addiction Treatment: A Research-Based Guide* (3<sup>rd</sup> edition). NIH Publication No. 12–4180. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse. Available: <http://www.drugabuse.gov/publications/principles-drug-addiction-treatment>

Presently, there is a lack of long-term outcomes data on patients who are discharged from addiction treatment programs. We challenge treatment programs and payers to measure the long-term outcomes of patients treated for substance use disorders following discharge, including abstinence. The data collected from these studies will significantly improve the outcomes of treatment programs and will help payers, patients, and patients' families identify programs that best achieve abstinence that moves them towards sustained long-term recovery.

This report describes strategies to measure long-term successful patient outcomes from addiction treatment. We explore three sources for outcome data collection: 1) addiction treatment programs, 2) outside evaluators including research organizations and consumer satisfaction organizations, and 3) addiction treatment payers, including insurance providers. There are many useful data elements that can be collected to determine long-term recovery outcomes. We focus on a few fundamental and practical ways to enhance and extend the present limited approach to evaluating treatment outcomes.

### **Approach #1: Standard Treatment Patient Outcome Assessment**

The first approach to evaluating patient outcomes is for addiction treatment programs to follow-up with patients and/or their families for an extended period of time after discharge, for both patients that complete treatment *and* for patients who leave against medical/program advice.

In preparation for this follow-up, at patient intake treatment programs should collect contact information for patients and designated family members to facilitate follow-up contacts. Patients and their families should understand at the outset of admission that the program will follow-up with them after the episode of treatment. Suggested follow-up outcome measurement intervals include one-year, three-years, and five-years post-discharge. The following sample data\* would be collected, ideally from patients directly, but possibly from family members, if appropriate. For this reason consent should be obtained from patients at intake for these data to be collected.

- » Following discharge from treatment was the patient monitored by the program for alcohol and other drug use (i.e. biological testing)?
- » Periods of abstinence (that are *not* substance-specific): through self-report, biological monitoring (if conducted) and treatment readmissions
  - > Less than 30 days / 30-90 days / 3-6 months / 6-12 months /12-18 months, etc.
- » Periods of relapse: through self-report, biological monitoring (if conducted) and treatment readmissions
  - > Self-report alcohol use since discharge from treatment: None / Occasionally / Monthly / Weekly / Daily
    - If yes, indicate: with problems/ without problems
  - > Number of heavy drinking days per month
  - > Self-report drug use since discharge from treatment: None / Occasionally / Monthly / Weekly / Daily
    - If yes, indicate: with problems/without problems
    - List of drugs used

---

\* The questions listed in this report are examples of useful data points to be collected. This report should not be used as a survey instrument but rather inform the development of survey instruments.

- > Circumstances that led to relapse(s)
  - > Changes in substances used and changes in frequency/quantity of use
- » Involvement in community-based recovery support (e.g. 12-steps): None / Occasionally / Monthly / Weekly / Daily
- » Recovery self-status evaluation: Do you consider yourself to be in recovery? Yes/No
- » Desire for recovery: Do you want to be in recovery? Yes/No
- » Employment/education status and recent history
- » Substance-related emergency department visits
- » Substance-related hospital admissions
- » Substance-use related illness/disease
- » Substance-related accidents (e.g. workplace, motor vehicle crashes)
- » Substance-related arrests/incarceration
- » Global functioning/quality of life
- » Psychological / subjective outcomes: cravings, mental health (anxiety/depression), overall health
- » Overall, how helpful was the treatment experience?
  - > 1 Extremely unhelpful / 2 Moderately unhelpful / 3 Somewhat unhelpful / 4 Neither helpful or unhelpful / 5 Somewhat helpful / 6 Moderately helpful / 7 Extremely helpful
- » What elements of the treatment experience were most and least helpful?
- » What activities following treatment were most and least helpful in maintaining recovery?

This is extensive list can be amended or shortened with the understanding that the focus needs to be on the extent to which the former patients are in sustained recovery, including being abstinent from alcohol and other drug use. It is unlikely that every addiction treatment program will be able to follow-up consistently with every patient over prolonged periods of time. Therefore, it is suggested that while every patient be contacted by programs as part of routine follow-up (e.g. 3 months), treatment programs conduct extensive follow-up with an admission cohort of patients through each follow-up interval at one-year, three-years and five-years post-discharge.

There are practical concerns and considerations associated with treatment programs conducting these internal evaluations of patient program outcomes. For example, treatment programs may have incentive to alter their data for marketing purposes showing inflated rates of success. Similarly, patients may not accurately report their own outcomes or alternately, only those who are doing well may be inclined to provide information about their outcomes following discharge. Additionally, because this approach to measuring patient outcomes wholly relies on practitioners to collect data and input the information on a consistent basis, this could become onerous and resource-intensive and it may be necessary to create incentives or requirements for treatment programs to collect these outcome data.

There are many differences between state and private treatment agencies and an absence of standardized reporting and central repositories may cause discrepancies between reporting. In all such programs, a modest level of oversight would ensure the integrity of data and findings. A potential solution to ease the data collection process for both state and private treatment programs, and to increase consistency across treatment programs, is the development of electronic options for assessments. Every addiction treatment program would use the same application and the data would

remain in a consistent format to be stored in a single location for that specific program. This would also permit aggregation and analysis of data from multiple treatment programs.

An important concern is confidentiality and ensuring privacy of patient information. It is presumed that private treatment programs own their data but would have the option of sharing their data to be pooled with data collected by state treatment agencies. Important questions to be addressed include to which national agency would the state treatment outcomes be reported, who is responsible for analyzing the data, and how would the data be publicized?

Thus, standard epidemiologically-driven questions that can be understood by every patient/family member need to be crafted to allow for analyses of the characteristics of persons who succeed and those who do not without information and selection bias.

## **Approach #2: Independent Outcome Assessment Focused on Patient Satisfaction**

A second approach to evaluating treatment outcomes is to use a framework similar to customer satisfaction research. In this model, a research entity outside the treatment program would follow-up with a representative sample of patients after discharge to report short- and long-term outcomes. In this model patients (and when possible, their family members) report their level of satisfaction with the treatment process and determine whether the specific episode of treatment met their desired outcomes. It could also identify the extent to which patients achieved sustained recovery and used recovery support services after treatment discharge. This model could stand alone or be complementary to Approach #1 in providing an *additional and confirming* system to evaluate treatment outcomes.

The independent research entity would contact all patients or an admission cohort following discharge from a treatment program. In anticipation of making these contacts, consent would need to be obtained at intake.

Ideally, the *same data items* in the previous Approach #1 would be collected from patients and the families, following discharge from treatment. These data relate to, among other items, periods of abstinence, periods of relapse, involvement in community-based recovery support, self-report recovery status and desire for recovery. Like Approach #1, the suggested follow-up intervals to collect this data include one-year, three-years and five-years post-discharge.

In addition to collecting the data items in Approach #1, in Approach #2, the independent research entity would collect data about the opinions of the treatment experience from both patients and their families. The following data would be collected from patients directly at one-year, three-years and five-years post-discharge:

- » On a scale from 1 to 7, how helpful was this episode of treatment?
  - > 1 Extremely unhelpful / 2 Moderately unhelpful / 3 Somewhat unhelpful / 4 Neither helpful or unhelpful / 5 Somewhat helpful / 6 Moderately helpful / 7 Extremely helpful
- » For patients receiving medication-assisted treatment, while in treatment, were you compliant with medication (i.e. buprenorphine or methadone) for your opiate use disorder?
  - > Not at all / Somewhat / Mostly / Completely

- » On a scale from 1 to 7, how helpful was treatment for a co-morbid psychological and/or psychiatric condition? (0 Did not participate)
- » Were you compliant with medication and/or therapy for your co-morbid disorder?
  - > Not at all / Somewhat / Mostly / Completely
- » On a scale from 1 to 7, how helpful was attending 12-Step meetings while in treatment? (0 Did not participate)
- » On a scale from 1 to 7, how helpful were group counseling sessions in treatment? (0 Did not participate)
- » On a scale from 1 to 7, how helpful were individual counseling sessions in treatment? (0 Did not participate)
- » On a scale from 1 to 7, how helpful were scheduled substance use screens in treatment? (0 Did not participate)
- » On a scale from 1 to 7, how helpful were random substance use screens in treatment? (0 Did not participate)
- » What was the approximate out-of-pocket cost to you personally?
  - > Lost earnings?
  - > Cost of treatment?
  - > Other costs?
- » Do you consider the costs of this treatment episode money well spent?
  - > Not at all / Somewhat / Mostly / Completely
  - > Why or why not?
- » Did this treatment program meet your expectations?
  - > Why or why not?
- » Would you recommend this treatment program to others with substance use disorders?
  - > No / Yes with reservations / Yes without reservations
  - > Why or why not?

In collecting patient outcome data using the self- and family-report model of Approach #1 and the customer satisfaction model of Approach #2, it must be understood that patients may be hostile to a treatment program due to the circumstances that led them to treatment admission and/or discharge in the first place. This approach could be particularly challenging for offender populations mandated to treatment, especially if relapse has the potential to result in sanctions. It would be important for the entity conducting this research (including the treatment program in Approach #1) to follow an admission cohort at the same interval for all patients and determine if the sample could be biased (e.g. only those who are doing well, or alternatively, those who had bad treatment experiences are likely to want to participate).

The independent entity collecting these outcome data should follow up with family members to determine the veracity of patient claims and to ascertain family opinions in relation to the treatment experience and patient progress post-discharge. This additional information would be particularly useful as some patients may not be able to fully assess their progress or could be in denial about relapse.

The following treatment program outcome measures could be collected by the independent entity through follow-up with designated family members of patients at the three intervals post-discharge:

- » On a scale from 1 to 7, how helpful was this episode of treatment to the patient?
  - > 1 Extremely unhelpful / 2 Moderately unhelpful / 3 Somewhat unhelpful / 4 Neither helpful or unhelpful / 5 Somewhat helpful / 6 Moderately helpful / 7 Extremely helpful
- » For patients receiving medication-assisted treatment, while in treatment, was the patient compliant with medication (i.e. buprenorphine or methadone)?
  - > Don't know / Not at all / Somewhat / Mostly / Completely
- » Was the patient treated for a co-morbid psychological and/or psychiatric condition as part of the substance use disorder treatment?
  - > Don't know / Yes / No
    - If yes, on a scale of 1 to 7, how helpful was this treatment?
  - > Was the patient compliant with medication and/or therapy for the co-morbid disorder?
    - Don't know / Not at all / Somewhat / Mostly / Completely
- » What was the approximate out-of-pocket cost to the patient (if known)?
  - > Lost earnings?
  - > Cost of treatment?
  - > Other costs?
- » Do you consider the costs of this treatment episode money well spent?
  - > Not at all / Somewhat / Mostly / Completely
  - > Why or why not?
- » Did this treatment program meet your expectations?
  - > Why or why not?
- » Would you recommend this treatment program to others with substance use disorders?
  - > No / Yes with reservations / Yes without reservations
  - > Why or why not?
- » Do you think the patient is in recovery? Yes / No

This broader data set collected by an independent entity would provide treatment programs with insight about how discharged patients perceive their treatment experiences as well as the perceptions of the value and impact of the treatment episode by family members. This information would inform addiction treatment programs to help them improve the quality of the services they provide to patients and their families.

### **Approach #3: Recovery-Oriented System Model and Health Care Payers as Consumers**


In this approach, healthcare payers (i.e. insurance companies, Medicaid, Medicare) track their patients' admissions to addiction treatment programs to identify the programs that yield the best outcomes, specifically measured by low re-admission rates. This approach is particularly useful in the current shift in health care delivery from fee-for-service to fee-for-performance. This form of evaluation encourages addiction treatment programs to focus on long-term care of patients. In this model, it is in the interest of all addiction treatment programs to ensure that re-admission rates after discharge, whether to their own programs or others following discharge, remain low. This approach will help payers identify programs that will result in costs-savings for the treatment of substance use disorders.

In order to produce low readmission rates, addiction treatment programs could be influenced to orient their care toward long-term recovery.




Figures A and B depict a system of care for substance use disorders. They demonstrate the shift from the starting point of problem drug use (i.e. substance use disorder) through possible stages and then to the achievement of recovery. Patients enter the system of care – either voluntarily or by mandate – to an episode of treatment. In an idealized seamless transition from addiction to recovery, patients would enter a formal addiction treatment program and be discharged after the episode of treatment is complete (at the medical recommendation of the program). Leading up to and after discharge, the individual would be closely connected to recovery support services with the goal of preventing relapse to substance use. After an extended period of abstinence – and improved state of personal health and engaged citizenship – the individual would reach the condition of recovery which would be maintained for a lifetime.

**Figure A.**



**Figure B.**



When relapse occurs, there is a need to immediately intervene with the individual, through recovery support services and possible readmission to treatment. Figures A and B show that is not just a treatment system supported by recovery support services, but the close interaction of episodes of treatment and relapse prevention services that create increasing periods of abstinence until recovery is ultimately achieved.

For addiction treatment programs to be recognized by healthcare payers as high-achieving in terms of long-term patient outcomes, the following information would be collected and analyzed:

- » Average wait times for program admission
- » Attrition rate / rate of successful patient treatment completion (discharge not against medical/program advice)
- » Rate of patient readmission to treatment
- » Periods of patient abstinence determined through:
  - > biological monitoring *in treatment* and *following treatment*
  - > treatment readmissions
- » Periods of patient relapse determined through:
  - > biological monitoring *in treatment* and *following treatment*
  - > treatment readmissions
- » Use of recovery support services (e.g. linkage to 12-step programs)
- » Connection to/coordination with primary care clinicians prior to discharge
- » Follow-up with the patients, families and primary care physicians
- » Substance-related emergency department visits
- » Substance-related hospital admissions
- » Substance-use related illness/disease
- » Substance-related accidents (e.g. workplace, motor vehicle crashes)
- » Substance-related arrests / incarceration

Like Approaches #1 and #2, there are limitations to Approach #3. One such limitation of Approach #3 is the risk of programs seeking to achieve “good” outcomes by limiting readmission in cases when treatment is needed. For this reason, in Approach #3, it would be useful to follow-up with a random sample of patients, independent from the insurance company, to ensure patients are getting the help they need and that the insurance companies are not simply avoiding readmission but that patients are abstinent and doing well. Denying readmission when treatment is needed is not a good outcome; when treatment is needed, it must be provided.

## Summary

Each of the three approaches to evaluate addiction treatment outcomes is distinct in its purpose, but all assume the objective of the desired outcome is complete and long-term abstinence from nonmedical use of addictive substances. Approach #1 requires treatment programs to evaluate their patient outcomes based on self-report (and biological monitoring, if available) through follow-up with patients one-year, three-years and five-years post-discharge.

Approach #2 builds on the data collected in Approach #1 by having an entity separate from the treatment programs follow up at one-year, three-years and five-years post-discharge with patients and

their families to capture their opinions about the quality and impact of the treatment provided. In each of these intervals, both patients and designated family members are contacted to determine specifically whether or not the treatment episode met their expectations.

Finally, Approach #3 focuses on the healthcare industry as a consumer interested in identifying the treatment programs that produce the best long-term results, including specifically low rates of readmission, and thus, produce the greatest cost-savings. This approach, while practical, comes with it the potential for short-changing the path to final recovery in the name of cost savings.

Over the course of the suggested follow-up intervals, some patients will be readmitted to the same or other addiction treatment programs. Likewise, the event that may have set an individual on the path to recovery may not be captured in these evaluations. There is no obvious way to ensure that treatment programs receive “credit” for helping individuals achieve recovery. It is most important now to develop new frameworks for addiction treatment programs to monitor long-term patient outcomes, for the benefit of patients and their families, to contain short- and long-term costs, and to ensure that referral is to the programs that produce the best long-term outcomes. This report is written to define the ultimate goal of treatment as well as to encourage this development of effective strategies to assess long-term outcomes of treatment.

## **Conclusions and General Recommendations for Improving Long-Term Patient Outcomes**

This report advocates for the creation of five-years of abstinence on a path to full recovery as the standard outcome measure of the treatment of individuals with substance use disorders. Although substance use disorders are serious chronic illnesses that require long-term care, the vast majority of addiction treatment programs provide only brief episodes of care. Use of the five-year standard requires the identification of what happens to patients after they are discharged from treatment.

The question of *how* patients with substance use disorders can best reach the desired outcome of five-year abstinence and full recovery is, for now, largely answered by the evidence provided by the systems of care management termed the New Paradigm for Recovery. These programs demonstrate that long-term abstinence and achieving a higher quality of life can be the outcome for a majority of patients regardless of the drugs they have used. In fact, recovery can be the expected outcome of treating and managing substance use disorders. Such programs require long-term active care management to extend and support relatively brief episodes of addiction treatment. This long-term monitoring of substance use disorders fits into the standard medical model of the care of many chronic diseases and can be managed in a variety of settings including primary care.

Achieving the proposed outcome of five-year abstinence and recovery requires long-term engagement of patients. This includes linking patients and their families prior to and following treatment discharge to primary care physicians for long-term care. It also includes long-term monitoring of substance use with random drug and alcohol tests either by the primary care physicians and/or by external monitoring services. Higher rates of achieving sustained recovery mean lower health care costs and improved health.

The three approaches to outcomes measurement proposed in this report suggest methods of documenting the long-term outcomes of patients treated for substance use disorders and have the potential to be implemented widely. Documenting the long-term outcomes of individuals with substance use disorders discharged from addiction treatment programs should lead to improved care and better delivery of services. Moreover, monitoring the long-term outcomes of patients should assist payers (and families) to assess which programs result in the best outcomes and the most cost-savings.

Making five-year abstinence and recovery a standard outcome measure of treatment evaluation and making these evaluations public could challenge treatment programs and clinicians to focus their efforts to achieve better long-term patient outcomes. Hopefully coupled with innovations in treatment, the demonstrated results of patient monitoring and management following addiction treatment will bring significant improvement in the nation's public health.

## Appendix: Current Substance Use Disorder Treatment Efficacy Standards

There are many varying models of addiction treatment. Some treatment models treat all types (and co-occurring) substance use disorders, while others prioritize the treatment of specific substance use disorders. Additionally, some forms of addiction treatment include the use of medication (e.g. buprenorphine, methadone).

Before reviewing the current treatment efficacy measures for treating addiction and specific substance use disorders, we first review terminology and how practices are evaluated as ‘evidence-based.’

### A. Defining ‘Efficacy’ and Evidence-Based Treatment Practices (EBPs)

The term evidence-based treatment refers to interventions, practices, and techniques that have proven to have positive or preferred outcomes through consistent scientific study.<sup>a b</sup> Because these interventions are validated by research to ‘work’ their wide implementation is encouraged. Efficacy and effectiveness are terms often used interchangeably; however, in the context of treatment outcomes, they have slightly different meanings. Treatment efficacy is the “clinical benefit produced by the intervention in the context of controlled research”, whereas effectiveness refers to the “clinical benefit produced in a clinical setting under naturalistic conditions” (p.95).<sup>c</sup>

The classification of interventions as evidence-based or effective requires high quality research designs. Randomized controlled trials (RCTs) or rigorous quasi-experimental designs are most commonly used for the purpose of demonstrating efficacy.<sup>d</sup> The accepted standard is a minimum of two rigorous studies with similar findings on key outcomes that demonstrated positive outcomes (see the Food and Drug Administration Model).

To critically evaluate a substance use disorder treatment study, the design is not the only element to consider. Different levels of evidentiary strength create a hierarchy by which researchers can draw conclusions about research findings.<sup>e</sup> These standards are as follows:

- » **Gold standard** – multiple replications of RCTs in different sites. There must be significant and sustained reductions in risk behaviors and controls for sample attrition. A preponderance of evidence supporting effectiveness across multiple sites is needed to meet this evidentiary standard. Research designs that adhere to the gold standard have high internal and external validity.

---

<sup>a</sup> Glasner-Edwards, S., & Rawson, R. A. (2010). Evidence-based practices in addiction treatment: review and recommendations for public policy. *Health Policy, 97*(2-3), 93-104.

<sup>b</sup> Taxman, F. S., & Belenko, S. (2012). *Implementing Evidence-Based Practices in Community Corrections and Addiction Treatment. Springer Series on Evidence-Based Crime Policy.* Springer Science+Business Media, LLC.

<sup>c</sup> Glasner-Edwards, S., & Rawson, R. A. (2010). Evidence-based practices in addiction treatment: review and recommendations for public policy. *Health Policy, 97*(2-3), 93-104.

<sup>d</sup> Taxman, F. S., & Belenko, S. (2012). *Implementing Evidence-Based Practices in Community Corrections and Addiction Treatment. Springer Series on Evidence-Based Crime Policy.* Springer Science+Business Media, LLC.

<sup>e</sup> Taxman, F. S., & Belenko, S. (2012). *Implementing Evidence-Based Practices in Community Corrections and Addiction Treatment. Springer Series on Evidence-Based Crime Policy.* Springer Science+Business Media, LLC.

- » **Silver standard** – quasi-experimental design with strong statistical controls but includes the same outcome and replication requirements as the more stringent gold standard.
- » **Bronze standard** – matched comparison groups without adequate statistical controls.

To determine whether an intervention is effective over time, it is recommended that a longitudinal design be employed in which data is collected at multiple intervals. In the context of the current discussion, extended longitudinal study is needed to assess long-term outcomes of specific interventions and treatments.

The implementation of an intervention is an additional consideration as factors related to delivery and practice can potentially influence treatment outcomes. For example, fidelity to the treatment model, practitioner buy-in and training, delivery setting, and can alter the way in which a patient experiences an intervention which could, subsequently, yield different effects –positive or negative.<sup>f</sup>

## B. Current EBP Classification Models and Approaches

A multitude of models and approaches are currently utilized by government agencies and the addiction field to determine whether treatment interventions are effective. Some models demand high levels of scientific rigor through RCTs whereas others rely upon synthesis of evidence and practitioner consensus as the basis for evidence-based designations. **Table 1** at the end of the Appendix provides an overview of several such models.

Regardless of the approach taken, the longer the study, the more information can be gathered about the effectiveness of the intervention. Longitudinal studies can identify optimal dosages, individual effective components of interventions, and the effectiveness of the intervention among different populations. It is this type of long-term follow-up (e.g., Phase IV in the NIH Guidelines) that elicits valuable information from a practice and performance measurement perspective as it sheds light on what is working well over time.

## C. Current Addiction Treatment Efficacy Measures

The following is a review of current efficacy measures used in clinical trials leading to labeled and off-label use for addiction treatment.

### Behavioral Therapy

Many studies include a psychotherapy component, commonly as an adjuvant to pharmacotherapy.<sup>g1</sup> Specific methodologies include:

- » Motivational enhancement therapy
- » Cognitive behavioral therapy
- » Contingency management

<sup>f</sup> Glasner-Edwards, S., & Rawson, R. A. (2010). Evidence-based practices in addiction treatment: review and recommendations for public policy. *Health Policy, 97*(2-3), 93-104.

<sup>g</sup> Danovitch, I., & Gorelick, D. A. (2012). State of the art treatments for cannabis dependence. *The Psychiatric Clinics of North America, 35*(2), (2):309–26.

- » Supportive-Expressive Psychotherapy
- » Community and family interventions

### Pharmacological Therapy

While short-term therapeutic endpoints may be adequate for some targets of addiction treatment, such as overdose and withdrawal, treatment for prevention of relapse and craving management require endpoints that focus on long-term efficacy. Although one may consider these as separate modalities of addiction therapy, it would be inappropriate to say that one approach can be used to obtain successful long-term outcomes, particularly since one cannot begin to consider prevention of relapse without initial adequate detoxification. In addition, treatment of substance dependence to prevent relapse may also serve to manage or prevent withdrawal symptoms; such as with nicotine replacement therapy and opioids for opioid maintenance, among others.

While specific pharmaceuticals used in treatment of underlying addiction vary by substance, efficacy endpoints utilized in clinical trials often focus on **relapse prevention, psychological and subjective progress, or social recovery**.

Relapse prevention is the primary goal of addiction treatment, allowing for full rehabilitation of patients to lives without substance dependence. Reason would imply that relapse prevention would exclusively refer to abstinence from the substance of use for the full course of a study, but in reality, some clinical trials focus on short-term abstinence of one to three weeks.<sup>h 2-6</sup> In defense of this method, some studies have suggested that continuous cocaine and alcohol abstinence of three weeks is predictive of long-term cocaine abstinence.<sup>7 i</sup> More lenient endpoints may not always be justified, but may be used due to a shorter study duration, high attrition<sup>j 8</sup>, or perhaps high variability of time to response among patients. Study durations range from 1 week to 2 years, varying widely between treatments of various substances. For example, studies of alcohol dependence range from 4 weeks to 2 years<sup>k 9</sup>, while duration of studies for treating cocaine dependence have a much shorter range of 5 to 25 weeks. Many studies only recorded outcomes for a mere 12 weeks. Although study duration varies, even in the case

<sup>h</sup> Castells, X., Casas, M., Pérez-Mañá, C., Roncero, C., Vidal, X., Capellà, D. (2010). Efficacy of psychostimulant drugs for cocaine dependence. *The Cochrane Database of Systematic Reviews*, (2), CD007380; Pani, P. P., Trogu, E., Vacca, R., Amato, L., Vecchi, S., & Davoli, M. (2010). Disulfiram for the treatment of cocaine dependence. *The Cochrane Database of Systematic Reviews*, (1), CD007024; Pani, P. P., Trogu, E., Vecchi, S., Amato, L. (2011). Antidepressants for cocaine dependence and problematic cocaine use. *The Cochrane Database of Systematic Reviews*, (12), CD002950; Nunes, E. V., McGrath, P. J., Quitkin, F. M., Ocepek-Welikson, K., Stewart, J.W., Koenig, T., Wager, S., & Klein, D.F. (1995). Imipramine treatment of cocaine abuse: possible boundaries of efficacy. *Drug and Alcohol Dependence*, 39(3), 185–95; Weinstein, A. M., & Gorelick, D. A. (2011). Pharmacological treatment of cannabis dependence. *Current Pharmaceutical Design*, 17(14), 1351-1358. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171994/> (Accessed March 14, 2014.)

<sup>i</sup> Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H-J. (2014). Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. *PLoS One*, 9(2), e87366.

<sup>j</sup> Cahill, K., Stead, L. F., & Lancaster, T. (2012). Nicotine receptor partial agonists for smoking cessation. *The Cochrane Database of Systematic Reviews*, (4), CD006103.

<sup>k</sup> Rösner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., & Soyka, M. (2010). Opioid antagonists for alcohol dependence. *The Cochrane Database of Systematic Reviews*, (12), CD001867.

of substantial duration of a year or more, primary endpoints for efficacy may be assessed at much sooner time points, rather than the full length of the study.<sup>1</sup> Another point of interest is that many studies choose retention in treatment as a surrogate for relapse prevention. Although retention in adequate treatment programs is vital to success of a recovering addict, it does not confer that a treatment is efficacious or that a subject does not relapse to some extent. Lastly, a quantification of substance use may be used to demonstrate a change in overall use. While this has the ability to demonstrate treatment efficacy, one cannot use these endpoints to assess whether a patient can attain complete abstinence from a substance with a particular treatment.

Psychological evaluations and subjective progress can be used to characterize a patient's recovery, their addiction severity (i.e. Addiction Severity Index, Clinical Global Impression score for dependence), cravings (i.e. Visual Analog Scale, Craving Analogue Scale, Voris Cocaine Craving Questionnaire, Obsessive Compulsive Drinking Scale), and/or withdrawal symptoms. Often, additional assessments for depression or anxiety are also included and evaluated. Finally, some studies also examine aspects of social recovery, such as avoidance of criminal activity or re-incarceration, and consistent employment. These endpoints might be considered somewhat secondary to preventing further substance use, but are significant when assessing the effects of treatment on all aspects of recovery.

**Table 2** at the end of the Appendix examines these endpoint categories in the context of various treatments for each substance-specific substance use disorder. The agents listed have been studied for their efficacy. Inclusion in this table does not imply that their efficacy has been established.

#### **D. Limitations of Current Efficacy Standards/Models**

Current research of treatment interventions suffer from a variety of methodological weaknesses. These include poor research design, unclear or varying definitions of research concepts, low internal and/or external validity, small sample sizes, and insufficient statistical calculations. The way in which the success or efficacy of treatment is measured also varies widely across studies.

Critical analysis of current substance use disorder treatment evidence standards revealed four major limitations:

1. **Follow-up intervals.** Findings of treatment intervention efficacy in the absence of any follow-up post-discharge or exit, fails to make a case for any long-term effects. Most interventions are relatively short in duration and while there may be positive effects in substance use during treatment, there is no way to determine whether those effects are sustained post-treatment. In order to determine whether there is lasting change in substance use behavior, follow-up is necessary. Moreover, a single follow-up interval within a few months of treatment cessation is not enough to establish a finding of prolonged recovery. To determine the duration or decay of effects, and to identify the conditions under which long-term sobriety may be achieved, a longitudinal or cohort study design spanning several years should be selected. This means the funding agencies

---

<sup>1</sup> Cahill, K., Stead, L. F., & Lancaster, T. (2012). Nicotine receptor partial agonists for smoking cessation. *The Cochrane Database of Systematic Reviews*, 4(4), CD006103.



must be willing to “pay it forward” and allow some grants to be extended years, rather than limiting them to just five years. The research team may not be able to discover how successful the treatment was if they are only allowed to follow the participants for one or two years. Reviewers need to understand the importance of longitudinal research. Too often major studies have been shut down when reviewers write on the summary statements that the study lacked innovation, that no new information would come from a longitudinal study, or that not enough publications had been written yet, when the final endpoint had not even been reached. Moreover, grant reviewers could benefit from training on the importance of these study designs.

2. **Outcome measure definitions.** The absence of standardization or uniform definitions for outcome measures can make comparisons among interventions challenging. For instance, measures such as sobriety, relapse, recovery, and alcohol and other drug use can each be defined very differently according to individual agencies or study methods. A similar problem exists in the criminal justice system with the outcome measure of recidivism. The lack of a uniform definition limits the ability to make accurate comparisons from one agency to another let alone from one jurisdiction to another. Moving forward, the development of standard, agreed-upon treatment outcome measures with universal definitions could be useful.
3. **Evidence threshold.** There is a lack of agreement among experts on a specific minimum threshold of evidence or cut-off point below which evidence should be considered insufficient for a finding of effectiveness.<sup>m</sup> Similarly, there is debate as to whether a small amount of evidence constitutes no evidence. There is great disparity in outcome effects for alcohol and other drug interventions. As the analysis demonstrated, some ‘evidence-based’ interventions have small or incremental positive results that are present only during the course of the intervention whereas other interventions have pronounced positive results that are sustained over time a much longer timeframe. Yet both may be deemed evidence-based.
4. **Treatment success.** The limitation of current substance use disorder treatment evidence is the lack of consensus regarding successful outcomes. It is this lack of consensus that motivates the development of the new standard proposed in this report. What treatment outcomes are deemed a success? Long-term recovery, decrease in alcohol and other drug use, or a certain amount of time between discharge and relapse? The answers to these questions are largely dependent on what standard the field wants to hold itself to and whether the perception of treatment success is long-term sobriety or if relapse is considered to be inevitable in most cases.

---

<sup>m</sup> Center for Substance Abuse Prevention. (2009). *Identifying and Selecting Evidence-Based Interventions: Revised Guidance Document for the Strategic Prevention Framework State Incentive Grant Program*. HHS Pub. No. (SMA)09-4205. Rockville, MD: Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration.

## Tables

Table 1 was developed by Erin Holmes, MA. Table 2 was developed by Amelia N. Deitchman, PharmD (PhD Candidate).

**Table 1. Substance Use Disorder Treatment Models and Requirements to Determine Effectiveness**

Model	Purpose and approach	Requirements
Food and Drug Administration (FDA) Guidelines	<p>The FDA is responsible for the review of scientific evidence to determine whether pharmaceutical treatments are safe for public consumption.</p> <p>In order for a medication to be approved by the FDA, there must be a substantial body of evidence that demonstrates that the drug is both safe and effective.</p>	<p>Rigorous standards</p> <p>Multiple, replicated RCTs</p> <p>High methodological quality of evidence</p> <p>Findings of a positive treatment effect relevant to target groups</p> <p>Findings replicated in a minimum of two different studies</p> <p>Overall consistency of evidence in the direction of effect</p> <p>Significant scientific agreement (Taxman and Belenko, 2011)</p>
National Institutes of Health (NIH) Guidelines	<p>The NIH guidelines translate and expand the FDA model applying it to behavioral health interventions. This model consists of four different phases of clinical trials to evaluate the effectiveness of treatment interventions.</p>	<p>Phase I trials involve a small test group of 20 to 80 subjects. It is at this stage that early indications and evidence of efficacy emerge. These initial trials also identify potential side effects, determine dosages, and evaluate the safety of the intervention (NIH, 2013).</p> <p>Phase II trials are larger and involve 100 to 300 subjects. The focus of this phase is to determine the efficacy of the treatment within a controlled setting and a focused target population.</p> <p>Phase III trials are conducted in multiple locations and settings where the researchers have less control over a larger number of subjects (1,000-3,000). The multisite nature and extended length of these trials allows researchers to collect longitudinal data and determine effectiveness over time, monitor potential side effects, and make comparisons to other interventions (NIH, 2013).</p> <p>Phase IV involves the continued collection of data after the interventions has been marketed.</p>
Center for Substance Abuse Prevention (CSAP) Guidelines	<p>The CSAP guidelines are used to classify treatment interventions as evidence-based.</p>	<p>Interventions must meet one or more of the following to be considered evidence-based:</p>

	<p>The approach utilized by CSAP is advantageous in that there are multiple criteria to determine whether evidence exists to establish effectiveness.</p>	<p>inclusion in Federal registries of evidence-based interventions (such as the National Registry of Evidence-Based Programs and Practices (NREPP)); reported in peer-reviewed journals with positive effects on the primary targeted outcome; and, documented evidence of effectiveness based on guidelines developed by the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Center for Substance Abuse Prevention (CSAP, 2009). These guidelines require that the intervention be: based on a theory of change that is documented in a conceptual model; similar in content and structure to other interventions that are found in Federal registries or academic literature. There should be documentation of instances of past implementation where there was attention to scientific standards of evidence with results that show a pattern of positive effects. The intervention should be “reviewed and deemed appropriate” by a panel of experts comprised of prevention researchers and practitioners (CSAP, 2009).</p>
<p>National Institute on Drug Abuse (NIDA) Principles</p>	<p>NIDA uses a consensus approach in formulating its <i>Principles of Drug Addiction Treatment</i> (Taxman and Belenko, 2011). The majority of the Principles are, in fact, considered to be best practices in the field as opposed to empirically validated EBPs. The use of a consensus approach can complement rigorous scientific study. The experiences of practitioners should not be undervalued as they have insight into the barriers and challenges associated with the translation of treatment research into practice in a real-world setting.</p>	<p>Qualitative methods such as focus groups and key informant interviews are used to obtain the professional opinion of practitioners about which practices and interventions they deem effective.</p>

### **Table 1 References**

Center for Substance Abuse Prevention. (2009). *Identifying and Selecting Evidence-Based Interventions: Revised Guidance Document for the Strategic Prevention Framework State Incentive Grant Program*. HHS Pub. No. (SMA)09-4205. Rockville, MD: Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration.

National Institutes of Health. (2013). "Clinical Trial", Glossary & Acronym List. National Institutes of Health, Office of Extramural Research.

Taxman, F. S., & Belenko, S. (2012). *Implementing Evidence-Based Practices in Community Corrections and Addiction Treatment*. Springer Series on Evidence-Based Crime Policy. Springer Science+Business Media, LLC.

**Table 2. Endpoints in the Treatment of Substance Use Disorders, by Substance**

Drug	Study Duration	Study Agents	Endpoints		
			Relapse Prevention	Psychological and subjective progress	Social Recovery
Nicotine <sup>8</sup>	24 to 52 weeks	varenicline <sup>10-29</sup> , bupropion sustained release <sup>13,14,17</sup> , and nicotine replacement <sup>10,11,27</sup>	Dropouts or treatment retention  Abstinence <ul style="list-style-type: none"> <li>• 7-day point-prevalence abstinence</li> <li>• Carbon monoxide-confirmed continuous abstinence at 9, 12, 24, and 52 weeks</li> <li>• Self-reported at 4 weeks, 6 months, and 2 years</li> <li>• Smoking less than 5 cigarettes during the previous 6 months, and none in the week prior to visit</li> </ul> Cigarettes per day 50% or more reduction  Timing and number of quit attempts	Cravings	
<b>Alcohol</b>					
Disulfiram <sup>7,30-36</sup>	8 to 52 weeks		Abstinence <ul style="list-style-type: none"> <li>• Time to first heavy drinking day</li> <li>• Number of abstinent days</li> <li>• Consecutive abstinence for 3 or 4 weeks</li> <li>• Continuous</li> </ul> Relapse		
Notes: In one study, the consumption of five or more drinks for men and four or more drinks for women was termed a “heavy drinking day”, while other studies used this definition to describe the “relapse” endpoint. Although other studies defined “relapse” slightly differently, as the consumption of more than five drinks in 24 hours (i.e. 40 g of alcohol).					

Drug	Study Duration	Study Agents	Relapse Prevention	Psychological and subjective progress	Social Recovery
<u>Opioid antagonists</u> <sup>9</sup>	4 to 54 weeks (mode 12 weeks)	naltrexone <sup>31,34,37-78</sup> , nalmeferne <sup>79-81</sup>	<p>Time to relapse, heavy drinking</p> <ul style="list-style-type: none"> <li>Variations in definitions range from <math>\geq 4</math> SDU to <math>\geq 9</math> SDU, with different cut-offs for men versus women in most cases. <b>Most common:</b> <math>\geq 5</math> SDU for men or 4 for women</li> <li>Drinking <math>\geq 5</math> days per week</li> </ul> <p>Degree of drinking</p> <ul style="list-style-type: none"> <li>Light, moderate, risky drinking with varying definitions</li> <li>Drinks per drinking day</li> <li>“Good clinical outcome” based on amount of drinking</li> </ul> <p>Abstinence</p> <ul style="list-style-type: none"> <li>Number of days</li> <li>Cumulative abstinence</li> </ul>	Cravings	
<u>Acamprosate</u> <sup>54,65,82-101</sup>	8 weeks to 24 months		<p>Time to relapse, heavy drinking: similar variations as described above</p> <ul style="list-style-type: none"> <li>Relapse duration</li> <li>Relapse severity</li> </ul> <p>Degree of drinking</p> <ul style="list-style-type: none"> <li>Percent heavy drinking days</li> <li>Drinks per drinking day</li> <li>“Good clinical outcome”</li> </ul> <p>Abstinence</p> <ul style="list-style-type: none"> <li>Days abstinent</li> <li>Continuous abstinence</li> <li>Between visit abstinence</li> <li>Time to first drink</li> </ul>	Craving (Clinical Global Impression Scale)	

Drug	Study Duration	Study Agents	Relapse Prevention	Psychological and subjective progress	Social Recovery
<u>Anticonvulsants</u> <sup>102</sup>	4 to 52 weeks	topiramate <sup>32,42,103-110</sup> , gabapentin <sup>111-115</sup> , valproate <sup>111,116,117</sup> , levetiracetam <sup>118,119</sup> , carbamazepine <sup>120-122</sup> , tiagabine <sup>123</sup>	<p>Time to relapse, heavy drinking: similar variations as described above</p> <ul style="list-style-type: none"> <li>• Heavy drinking with or without problems</li> <li>• Dropouts</li> <li>• Minor, major, severe relapse</li> </ul> <p>Degree of drinking</p> <ul style="list-style-type: none"> <li>• Moderate drinking</li> <li>• Sustained heavy drinking days: 3 consecutive heavy drinking days</li> <li>• Duration of heavy drinking</li> <li>• Drinks per drinking day, week</li> </ul> <p>Abstinence</p> <ul style="list-style-type: none"> <li>• Days abstinent</li> <li>• Complete abstinence</li> <li>• Continuous abstinence</li> </ul>	Cravings (OCDS and Craving Analogue Scale)	
<b>Opiates</b>					
<u>Methadone</u> <sup>124-190</sup>	1 month to 2 years		<p>Relapse</p> <ul style="list-style-type: none"> <li>• Heroin use: hair analysis and self-report</li> <li>• Illicit drug use: urine drug screen and self-report for heroin, amphetamines, cocaine, barbiturates and alcohol; Frequency ranged from monthly to daily collection</li> <li>• Program retention, compliance, continued treatment post-study</li> </ul> <p>Risk behavior</p> <ul style="list-style-type: none"> <li>• HIV, HCV seroprevalence</li> <li>• Syringe sharing</li> </ul>	Health Mortality	Employment Education Reincarceration

Drug	Study Duration	Study Agents	Relapse Prevention	Psychological and subjective progress	Social Recovery
<u>Naltrexone</u> <sup>172,191-203</sup>	1 to 12 months (avg 6 months)		<p>Relapse</p> <ul style="list-style-type: none"> <li>Retention in treatment</li> <li>Retention without relapse</li> <li>Days to drug use: urine drug screen</li> </ul> <p>Abstinence</p> <ul style="list-style-type: none"> <li>Monthly abstinence</li> <li>Complete abstinence</li> </ul>	Cravings	Reincarceration
<u>Buprenorphine +/- naloxone</u> <sup>124,135-137,142,160-184,186-190</sup>	2 to 52 weeks		<p>Relapse</p> <ul style="list-style-type: none"> <li>Retention in treatment, compliance (attendance)</li> <li>Drug use: self-report and urine drug screen for opioids, cocaine, amphetamines, cannabis, and benzodiazepines, breath alcohol</li> </ul> <p>Treatment dosage</p> <ul style="list-style-type: none"> <li>% taking original dose</li> <li>% requesting dose change</li> <li>Dose adequacy</li> </ul> <p>Continuous Abstinence</p>	<p>Cravings</p> <p>Opioid withdrawal ratings</p> <p>Dependence severity rating by patient</p> <p>Psychosocial adjustment and psychopathology</p>	Incarceration, criminal behavior
<u>Psychosocial Combined with Maintenance Therapy</u> <sup>204-215</sup>	6 to 48 weeks		<p>Relapse</p> <ul style="list-style-type: none"> <li>Retention in treatment</li> <li>Compliance to counseling; adherence</li> </ul> <p>Degree of use by urine drug screen</p> <p>Abstinence</p> <ul style="list-style-type: none"> <li>3 consecutive weeks</li> </ul>	<p>Severity of dependence as addiction severity index (ASI) and risk assessment battery</p> <p>Average maintenance treatment dose</p> <p>Psychiatric symptoms/psychological distress</p> <ul style="list-style-type: none"> <li>Internal-External Locus of Control</li> <li>Interpersonal Trust</li> <li>State-Trait Anxiety</li> <li>Social Desirability</li> </ul>	<p>Employment</p> <p>Academic involvement</p> <p>Criminal activity</p>



Drug	Study Duration	Study Agents	Relapse Prevention	Psychological and subjective progress	Social Recovery
				<ul style="list-style-type: none"> <li>• Depression</li> <li>• Assertion</li> <li>• Pleasant Events</li> <li>• Beck Depression Inventory with Symptom Check List-90</li> </ul> Cravings	
<b>Cocaine/Stimulants</b>					
<u>Psychostimulants</u> <sup>2</sup>	6 to 24 weeks	modafinil <sup>216</sup> , selegiline <sup>217</sup> , methylphenidate IR and SR <sup>218-220</sup> , dextroamphetamine IR and SR <sup>221-224</sup> , mazindol IR <sup>225-228</sup> , bupropion IR and SR <sup>229-231</sup>	Relapse <ul style="list-style-type: none"> <li>• Retention in treatment</li> <li>• Self-reported use 1-3 times weekly urine drug screen</li> </ul> Continuous abstinence for 2 or 3 weeks	Cravings (VAS, brief substance craving scale (BSCS), cocaine craving questionnaire (CCQ), or Tiffany Cocaine Craving Scale)	
<u>Disulfiram</u> <sup>3,74,232-237</sup>	11 to 12 weeks		Relapse <ul style="list-style-type: none"> <li>• Retention in treatment</li> <li>• Abstinence duration with and without alcohol</li> </ul> Degree of use <ul style="list-style-type: none"> <li>• Frequency and intensity of use: days per week, grams per week</li> <li>• Urine drug screen 3 times per week</li> <li>• Dollar value of daily cocaine use</li> </ul> Abstinence: days to continuous abstinence for 3 weeks	Cravings (VAS) Addiction severity index	
<u>Anticovulsants</u> <sup>238</sup>	1 to 24 weeks	lamotrigine <sup>239</sup> , gabapentin <sup>239-241</sup> , carbamazepine <sup>242-247</sup> , phenytoin <sup>248,249</sup> , tiagabine <sup>241,250,251</sup> , topiramate <sup>252</sup>	Relapse: Study dropout  Degree of use <ul style="list-style-type: none"> <li>• Self-reported</li> <li>• Thrice weekly urine drug screen</li> </ul> Weekly abstinence	Cravings	

Drug	Study Duration	Study Agents	Relapse Prevention	Psychological and subjective progress	Social Recovery
<u>Antidepressants</u> <sup>4</sup>	2 to 25 weeks	imipramine <sup>5</sup> , desipramine <sup>176,243,253-267</sup> , fluoxetine <sup>268-272</sup> , nefazodone <sup>273,274</sup> , paroxetine <sup>275</sup> , venlafaxine <sup>275</sup> , ritanserin <sup>276,277</sup> , selegiline <sup>217</sup> , buspirone <sup>278</sup> , gepirone <sup>279</sup> , L-tryptophan <sup>280</sup> , bupropion <sup>229-231</sup> , citalopram <sup>281</sup> , sertraline <sup>251</sup>	Relapse <ul style="list-style-type: none"> <li>• Retention to treatment</li> <li>• Attendance to psychological program</li> <li>• Overall abstinence</li> </ul> Severity of use <ul style="list-style-type: none"> <li>• Self-reported use</li> <li>• 13-items Quantitative Cocaine Inventory (QCI)</li> <li>• Urine drug screen</li> <li>• Cocaine use inventory</li> <li>• Weekly frequency, amount, route of use</li> </ul> Abstinence <ul style="list-style-type: none"> <li>• Longest period of continuous abstinence</li> <li>• Continuous abstinence for 3 weeks</li> </ul>	Cravings (cocaine craving scale, VAS)  Addiction severity index	
<u>Dopamine agonists</u> <sup>282</sup>	1.5 to 16 weeks	carbidopa/levodopa <sup>283-286</sup> , amantadine <sup>254,263,266,287-293</sup> , pramipexole <sup>275</sup>	Relapse: <ul style="list-style-type: none"> <li>• Retention to treatment, attendance</li> <li>• Study dropouts</li> <li>• Abstinence</li> </ul> Degree of use by urine drug screen	Cravings	
<u>Antipsychotics</u> <sup>294</sup>	5-168 days	haloperidol <sup>295</sup> , risperidone <sup>222,296</sup> , olanzapine <sup>297-299</sup>	Relapse: Retention in treatment  Degree of use by urine drug screen	Cravings: VAS, Voris Cocaine Craving Questionnaire  Severity of dependence: Clinical Global Impression Scale (CGIS), Addiction Severity Index (ASI)	
<u>Cannabis</u> <sup>1,6</sup>	11-13 weeks	dronabinol <sup>300</sup> , lofexidine, divalproex <sup>301</sup> , nefazodone <sup>302</sup> , bupropion SR <sup>302</sup> , lithium [for withdrawal] <sup>303</sup> , entacapone.	Relapse <ul style="list-style-type: none"> <li>• Treatment retention</li> <li>• Time to dropout</li> </ul> Degree of use <ul style="list-style-type: none"> <li>• Self-reported use – strong</li> </ul>	Craving (Marijuana Craving Questionnaire)  Severity of dependence: CGIS	

Drug	Study Duration	Study Agents	Relapse Prevention	Psychological and subjective progress	Social Recovery
		atomoxetine <sup>304,305</sup> , buspirone <sup>306</sup> , fluoxetine	correspondence to urine drug screen <sup>300</sup> <ul style="list-style-type: none"> <li>• Days of use per week</li> <li>• Hits per day<sup>307</sup></li> <li>• Urine drug screens (except when treated with dronabinol) for cannabinoids, opiates, methadone, barbiturates, amphetamine and cocaine</li> <li>• Dollar amount spent on cannabis since last visit</li> </ul> Abstinence <ul style="list-style-type: none"> <li>• Number consecutive days of abstinence</li> <li>• Abstinence during the final 2 weeks of treatment</li> <li>• 3 consecutive weeks of abstinence</li> </ul>		
Notes: Interestingly, one study <sup>308</sup> followed a group of ten adolescents treated with 12 weeks of fluoxetine for major depression with comorbid alcohol and cannabis abuse. After one, three, and five years, dependence was determined based on DSM-IV criteria. This is the only study found with such extensive follow-up that used diagnostic criteria to evaluate absence of dependence.					

## Table 2. References

1. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. *Psychiatr Clin North Am.* 2012;35(2):309–26. doi:10.1016/j.psc.2012.03.003.
2. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. *Cochrane database Syst Rev.* 2010;(2):CD007380. doi:10.1002/14651858.CD007380.pub3.
3. Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. *Cochrane database Syst Rev.* 2010;(1):CD007024. doi:10.1002/14651858.CD007024.pub2.
4. Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. *Cochrane database Syst Rev.* 2011;(12):CD002950. doi:10.1002/14651858.CD002950.pub3.
5. Nunes E V, McGrath PJ, Quitkin FM, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. *Drug Alcohol Depend.* 1995;39(3):185–95. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8556967>. Accessed March 14, 2014.
6. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. *Curr Pharm Des.* 2011;17(14):1351–8. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3171994&tool=pmcentrez&rendertype=abstract>. Accessed March 14, 2014.
7. Skinner MD, Lahmek P, Pham H, Aubin H-J. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. *PLoS One.* 2014;9(2):e87366. doi:10.1371/journal.pone.0087366.
8. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane database Syst Rev.* 2012;4(4):CD006103. doi:10.1002/14651858.CD006103.pub6.
9. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. *Cochrane database Syst Rev.* 2010;(12):CD001867. doi:10.1002/14651858.CD001867.pub2.
10. Aubin H-J, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax.* 2008;63(8):717–24. doi:10.1136/thx.2007.090647.
11. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):64–71. doi:10.1001/jama.296.1.64.
12. Bolliger CT, Issa JS, Posadas-Valay R, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. *Clin Ther.* 2011;33(4):465–77. doi:10.1016/j.clinthera.2011.04.013.
13. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):47–55. doi:10.1001/jama.296.1.47.
14. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):56–63. doi:10.1001/jama.296.1.56.
15. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. *Clin Ther.* 2007;29(6):1040–56. doi:10.1016/j.clinthera.2007.06.012.
16. Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. *Curr Med Res Opin.* 2008;24(7):1931–41. doi:10.1185/03007990802177523.
17. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. *Arch Intern Med.* 2006;166(15):1561–8. doi:10.1001/archinte.166.15.1561.
18. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch Intern Med.* 2006;166(15):1571–7. doi:10.1001/archinte.166.15.1571.
19. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry.* 2012;73(5):654–60. doi:10.4088/JCP.11m07522.

20. Rennard S, Hughes J, Cinciripini PM, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. *Nicotine Tob Res.* 2012;14(3):343–50. doi:10.1093/ntr/ntr220.
21. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation.* 2010;121(2):221–9. doi:10.1161/CIRCULATIONAHA.109.869008.
22. Smith BJ, Carson KV, Brinn MP, et al. Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients. *Thorax.* 2013;68(5):485–6. doi:10.1136/thoraxjnl-2012-202484.
23. Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. *Addict Behav.* 2011;36(12):1127–32. doi:10.1016/j.addbeh.2011.07.002.
24. Swan GE, McClure JB, Jack LM, et al. Behavioral counseling and varenicline treatment for smoking cessation. *Am J Prev Med.* 2010;38(5):482–90. doi:10.1016/j.amepre.2010.01.024.
25. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. *Chest.* 2011;139(3):591–9. doi:10.1378/chest.10-0865.
26. Tsai S-T, Cho H-J, Cheng H-S, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. *Clin Ther.* 2007;29(6):1027–39. doi:10.1016/j.clinthera.2007.06.011.
27. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). *Circ J.* 2010;74(4):771–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20154405>. Accessed June 20, 2014.
28. Wang C, Xiao D, Chan KPW, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. *Respirology.* 2009;14(3):384–92. doi:10.1111/j.1440-1843.2008.01476.x.
29. Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. *Curr Med Res Opin.* 2007;23(4):793–801. doi:10.1185/030079907X182185.
30. Laaksonen E, Koski-Jännes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. *Alcohol Alcohol.* 2008;43(1):53–61. doi:10.1093/alcalc/agh136.
31. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. *Biol Psychiatry.* 2005;57(10):1128–37. doi:10.1016/j.biopsych.2005.02.016.
32. De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. *J Subst Abuse Treat.* 2008;34(4):460–3. doi:10.1016/j.jsat.2007.05.012.
33. Nava F, Premi S, Manzato E, Lucchini A. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst. *J Psychoactive Drugs.* 2006;38(3):211–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17165363>. Accessed March 7, 2014.
34. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. *Arch Gen Psychiatry.* 1992;49(11):881–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1444726>. Accessed March 7, 2014.
35. De Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. *Alcohol Alcohol.* 2004;39(6):528–31. doi:10.1093/alcalc/agh104.
36. De Sousa A, De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. *Alcohol Alcohol.* 2005;40(6):545–8. doi:10.1093/alcalc/agh187.
37. Ahmadi J, Ahmadi N. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. *Ger J Psychiatry.* 2002;5(4):85–9.
38. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. *Am J Psychiatry.* 1999;156(11):1758–64. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10553740>. Accessed June 20, 2014.

39. Anton RF, Moak DH, Latham P, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. *J Clin Psychopharmacol*. 2005;25(4):349–57. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16012278>. Accessed June 20, 2014.
40. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. *JAMA*. 2006;295(17):2003–17. doi:10.1001/jama.295.17.2003.
41. Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. *Alcohol Clin Exp Res*. 2003;27(7):1142–9. doi:10.1097/01.ALC.0000075548.83053.A9.
42. Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. *Addiction*. 2008;103(12):2035–44. doi:10.1111/j.1360-0443.2008.02355.x.
43. Brown ES, Carmody TJ, Schmitz JM, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. *Alcohol Clin Exp Res*. 2009;33(11):1863–9. doi:10.1111/j.1530-0277.2009.01024.x.
44. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. *Alcohol Alcohol*. 2000;35(6):587–93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11093966>. Accessed June 20, 2014.
45. Galarza NJ, Díaz Ramírez D, Guzmán F, Caballero JA, Martínez AJ. The use of naltrexone to treat ambulatory patients with alcohol dependence. *Bol Asoc Med P R*. 1997;89(10-12):157–60. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9577049>. Accessed June 20, 2014.
46. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *JAMA*. 2005;293(13):1617–25. doi:10.1001/jama.293.13.1617.
47. Gastpar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. *J Clin Psychopharmacol*. 2002;22(6):592–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12454559>. Accessed June 20, 2014.
48. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. *Alcohol Clin Exp Res*. 2002;26(9):1381–7. doi:10.1097/01.ALC.0000030561.15921.A9.
49. Heinälä P, Alho H, Kiiänmaa K, Lönnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. *J Clin Psychopharmacol*. 2001;21(3):287–92. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11386491>. Accessed May 28, 2014.
50. Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. *Psychopharmacology (Berl)*. 1998;139(1-2):44–52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9768541>. Accessed June 20, 2014.
51. Huang M-C, Chen C-H, Yu J-M, Chen C-C. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. *Addict Biol*. 2005;10(3):289–92. doi:10.1080/13556210500223504.
52. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. *Alcohol Clin Exp Res*. 2000;24(5):737–42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10832917>. Accessed June 20, 2014.
53. Johnson BA, Ait-Daoud N, Aubin H-J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. *Alcohol Clin Exp Res*. 2004;28(9):1356–61. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15365306>. Accessed June 20, 2014.
54. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. *Arch Gen Psychiatry*. 2003;60(1):92–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12511176>. Accessed June 20, 2014.
55. Killeen TK, Brady KT, Gold PB, et al. Effectiveness of naltrexone in a community treatment program. *Alcohol Clin Exp Res*. 2004;28(11):1710–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15547458>. Accessed June 20, 2014.

56. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. *Alcohol Clin Exp Res*. 1998;22(5):1074–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9726277>. Accessed June 20, 2014.
57. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. *Neuropsychopharmacology*. 2000;22(5):493–503. doi:10.1016/S0893-133X(99)00135-9.
58. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. *Alcohol Clin Exp Res*. 2004;28(7):1051–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15252291>. Accessed June 20, 2014.
59. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. *N Engl J Med*. 2001;345(24):1734–9. doi:10.1056/NEJMoa011127.
60. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. *Med J Aust*. 2002;176(11):530–4. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12064984>. Accessed June 20, 2014.
61. Lee A, Tan S, Lim D, et al. Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. *Drug Alcohol Rev*. 2001;20(2):193–99.
62. Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. *J Psychopharmacol*. 2009;23(2):123–9. doi:10.1177/0269881108089596.
63. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. *Am J Addict*. 2001;10(3):258–68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11579624>. Accessed June 20, 2014.
64. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. *Alcohol Clin Exp Res*. 2001;25(11):1634–47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11707638>. Accessed June 20, 2014.
65. Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. *Addiction*. 2006;101(10):1451–62. doi:10.1111/j.1360-0443.2006.01555.x.
66. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. *Addiction*. 2001;96(11):1565–73. doi:10.1080/09652140120080705.
67. O’Malley SS, Robin RW, Levenson AL, et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. *Alcohol Clin Exp Res*. 2008;32(7):1271–83. doi:10.1111/j.1530-0277.2008.00682.x.
68. O’Malley SS, Sinha R, Grilo CM, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. *Alcohol Clin Exp Res*. 2007;31(4):625–34. doi:10.1111/j.1530-0277.2007.00347.x.
69. Oslin D, Liberto JG, O’Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. *Am J Geriatr Psychiatry*. 1997;5(4):324–32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9363289>. Accessed June 20, 2014.
70. Oslin DW. Treatment of late-life depression complicated by alcohol dependence. *Am J Geriatr Psychiatry*. 2005;13(6):491–500. doi:10.1176/appi.ajgp.13.6.491.
71. Oslin DW, Lynch KG, Pettinati HM, et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. *Alcohol Clin Exp Res*. 2008;32(7):1299–308. doi:10.1111/j.1530-0277.2008.00698.x.
72. Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. *Psychopharmacology (Berl)*. 2004;172(3):291–7. doi:10.1007/s00213-003-1658-9.
73. Pettinati HM, Kampman KM, Lynch KG, et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. *J Subst Abuse Treat*. 2008;34(4):378–90. doi:10.1016/j.jsat.2007.05.011.

74. Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. *Addict Behav.* 2008;33(5):651–67. doi:10.1016/j.addbeh.2007.11.011.
75. Schmitz JM, Lindsay JA, Green CE, Herin D V, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-alcohol dependence. *Am J Addict.* 2009;18(5):356–62. doi:10.3109/10550490903077929.
76. Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. *Am J Addict.* 2004;13(4):333–41. doi:10.1080/10550490490480982.
77. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. *Arch Gen Psychiatry.* 1992;49(11):876–80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1345133>. Accessed June 20, 2014.
78. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. *Arch Gen Psychiatry.* 1997;54(8):737–42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9283509>. Accessed June 20, 2014.
79. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. *Arch Gen Psychiatry.* 1999;56(8):719–24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10435606>. Accessed June 20, 2014.
80. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. *Alcohol Clin Exp Res.* 1994;18(5):1162–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7847600>. Accessed June 20, 2014.
81. Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. *J Clin Psychopharmacol.* 2004;24(4):421–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15232334>. Accessed June 20, 2014.
82. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. *Cochrane database Syst Rev.* 2010;(9):CD004332. doi:10.1002/14651858.CD004332.pub2.
83. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. *J Stud Alcohol.* 2004;65(1):136–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15000513>. Accessed June 20, 2014.
84. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. *Alcohol Clin Exp Res.* 1998;22(3):573–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9622434>. Accessed June 20, 2014.
85. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. *Alcohol Alcohol.* 2000;35(2):176–87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10787394>. Accessed May 28, 2014.
86. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and Prevention of Relapse in Alcoholics: Results of a Randomized, Placebo-Controlled, Double-Blind Study in Out-Patient Alcoholics in the Netherlands, Belgium and Luxembourg. *Eur Addict Res.* 1997;3:129–137.
87. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. *Alcohol Alcohol.* 2001;36(5):413–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11524307>. Accessed March 11, 2014.
88. Ladewig D, Knecht T, Leher P, Fendl A. Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients. *Ther Umsch.* 1993;50(3):182–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8475472>. Accessed June 20, 2014.
89. Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. *Alcohol Alcohol.* 1990;25(6):613–22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2085344>. Accessed June 20, 2014.
90. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. *J Psychiatr Res.* 2006;40(5):383–93. doi:10.1016/j.jpsychires.2006.02.002.
91. Barrias J, Chabac S, Ferreira L, Fonte A, Potgieter A, Teixeira de Sousa E. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. *Psiquiatr Clin.* 1997;18:149–60.



92. Namkoong K, Lee B-O, Lee P-G, Choi M-J, Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. *Alcohol Alcohol*. 2003;38(2):135–41. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12634260>. Accessed June 20, 2014.
93. Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. *Eur Child Adolesc Psychiatry*. 2003;12(3):144–8. doi:10.1007/s00787-003-0327-1.
94. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. *Alcohol Alcohol*. 1995;30(2):239–47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7662044>. Accessed June 20, 2014.
95. Pelc I, Le Bon O, Lehert P, Verbanck P. Acamprosate in the treatment of alcohol dependence: A six month post detoxification study. In: Naranjo C, Sellers E, eds. *Novel pharmacological interventions for alcoholism*. New York: Springer; 1992:348–52.
96. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. *Br J Psychiatry*. 1997;171:73–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9328500>. Accessed June 20, 2014.
97. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. *Addiction*. 1997;92(11):1537–46. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9519495>. Accessed June 20, 2014.
98. Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? *J Pharm Belg*. 1996;51(2):65–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8786520>. Accessed June 20, 2014.
99. Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. *Arch Gen Psychiatry*. 1996;53(8):673–80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8694680>. Accessed June 20, 2014.
100. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. *Alcohol Alcohol*. 2000;35(2):202–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10787398>. Accessed June 20, 2014.
101. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. *Lancet*. 1996;347(9013):1438–42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8676626>. Accessed June 20, 2014.
102. Pani PP, Trogu E, Pacini M, Maremmanni I. Anticonvulsants for alcohol dependence. *Cochrane database Syst Rev*. 2014;2(2):CD008544. doi:10.1002/14651858.CD008544.pub2.
103. Rubio G, Martínez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. *J Clin Psychopharmacol*. 2009;29(6):584–9. doi:10.1097/JCP.0b013e3181bfbdb79.
104. Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. *BMC Psychiatry*. 2011;11:41. doi:10.1186/1471-244X-11-41.
105. Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. *Drug Alcohol Depend*. 2013;133(2):440–6. doi:10.1016/j.drugalcdep.2013.06.032.
106. Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O'Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. *Drug Alcohol Depend*. 2013;133(1):94–9. doi:10.1016/j.drugalcdep.2013.05.026.
107. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. *JAMA*. 2007;298(14):1641–51. doi:10.1001/jama.298.14.1641.
108. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. *Lancet*. 2003;361(9370):1677–85. doi:10.1016/S0140-6736(03)13370-3.
109. Flórez G, Saiz PA, García-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. *Eur Addict Res*. 2011;17(1):29–36. doi:10.1159/000320471.

110. Flórez G, García-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. *Alcohol Clin Exp Res*. 2008;32(7):1251–9. doi:10.1111/j.1530-0277.2008.00680.x.
111. Trevisan LA, Ralevski E, Keegan K, et al. Alcohol Detoxification and Relapse Prevention Using Valproic Acid Versus Gabapentin in Alcohol-dependent Patients. *Addict Disord Their Treat*. 2008;7(3):119–128.
112. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2007;68(11):1691–700. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18052562>. Accessed June 20, 2014.
113. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. *Alcohol Clin Exp Res*. 2008;32(8):1429–38. doi:10.1111/j.1530-0277.2008.00706.x.
114. Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. *Am J Psychiatry*. 2011;168(7):709–17. doi:10.1176/appi.ajp.2011.10101436.
115. Anton RF, Myrick H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. *J Clin Psychopharmacol*. 2009;29(4):334–42. doi:10.1097/JCP.0b013e3181aba6a4.
116. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. *Arch Gen Psychiatry*. 2005;62(1):37–45. doi:10.1001/archpsyc.62.1.37.
117. Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. *Drug Alcohol Depend*. 2002;67(3):323–30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12127203>. Accessed June 20, 2014.
118. Richter C, Effenberger S, Bschor T, et al. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. *J Clin Psychopharmacol*. 2012;32(4):558–62. doi:10.1097/JCP.0b013e31825e213e.
119. Fertig JB, Ryan ML, Falk DE, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. *Alcohol Clin Exp Res*. 2012;36(8):1421–30. doi:10.1111/j.1530-0277.2011.01716.x.
120. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. *Alcohol Clin Exp Res*. 1997;21(1):86–92. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9046378>. Accessed June 20, 2014.
121. Martinotti G, Romanelli R, Di Nicola M, Reina D, Mazza M, Janiri L. Oxcarbazepine at high dosages for the treatment of alcohol dependence. *Am J Addict*. 2007;16(3):247–8. doi:10.1080/10550490701375558.
122. Croissant B, Diehl A, Klein O, et al. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. *Alcohol Clin Exp Res*. 2006;30(4):630–5. doi:10.1111/j.1530-0277.2006.00082.x.
123. Paparrigopoulos T, Tzavellas E, Karaiskos D, Malitas P, Liappas I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. *J Psychopharmacol*. 2010;24(9):1375–80. doi:10.1177/0269881109103799.
124. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane database Syst Rev*. 2014;2(2):CD002207. doi:10.1002/14651858.CD002207.pub4.
125. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. *Cochrane database Syst Rev*. 2003;(3):CD002208. doi:10.1002/14651858.CD002208.
126. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane database Syst Rev*. 2009;(3):CD002209. doi:10.1002/14651858.CD002209.pub2.
127. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. *Med J Aust*. 1991;154(3):195–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1988793>. Accessed June 20, 2014.
128. Caplehorn J, Dalton M, Cluff M, Petrenas A. Retention in methadone maintenance and heroin addicts' risk of death. *Addiction*. 1994;89(2):203–207.
129. Caplehorn JR, Irwig L, Saunders JB. Physicians' attitudes and retention of patients in their methadone maintenance programs. *Subst Use Misuse*. 1996;31(6):663–77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8816115>. Accessed June 20, 2014.

130. D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. *Drug Alcohol Depend.* 1998;52(2):167–71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9800146>. Accessed June 20, 2014.
131. Del Rio M, Mino A, Perneger T V. Predictors of patient retention in a newly established methadone maintenance treatment programme. *Addiction.* 1997;92(10):1353–60. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9489052>. Accessed June 20, 2014.
132. Gaughwin M, Solomon P, Ali R. Correlates of retention on the South Australian Methadone Program 1981–91. *Aust N Z J Public Health.* 1998;22(7):771–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9889441>. Accessed June 20, 2014.
133. Goldstein A, Judson BA. Proceedings: Efficacy and side effects of three widely different methadone doses. *Proc Natl Conf Methadone Treat.* 1973;1:21–44. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4612369>. Accessed June 20, 2014.
134. Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. *Drug Alcohol Depend.* 2001;62(3):255–64. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11295330>. Accessed June 20, 2014.
135. Johnson RE, Fudala PJ. Background and design of a controlled clinical trial (ARC 090) for the treatment of opioid dependence. *NIDA Res Monogr.* 1992;128:14–24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1436012>. Accessed June 20, 2014.
136. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *N Engl J Med.* 2000;343(18):1290–7. doi:10.1056/NEJM200011023431802.
137. Oliveto A, Kosten T, Schottenfeld R, Ziedonis D, Falcioni J. Cocaine use in buprenorphine vs methadone-maintained patients. *Am J Addict.* 1994;3(1):43–48.
138. Ling W, Charuvastra C, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. *Arch Gen Psychiatry.* 1976;33(6):709–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/779705>. Accessed June 20, 2014.
139. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. *Arch Gen Psychiatry.* 2000;57(4):395–404. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10768702>. Accessed June 20, 2014.
140. Grabowski J, Rhoades H, Elk R, Schmitz J, Creson D. Methadone dosage, cocaine and opiate abuse. *Am J Psychiatry.* 1993;150(4):675. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8465894>. Accessed June 20, 2014.
141. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. *Am J Public Health.* 1998;88(1):34–9. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1508390&tool=pmcentrez&rendertype=abstr>. Accessed June 20, 2014.
142. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in Buprenorphine- versus methadone-maintained patients. *J Nerv Ment Dis.* 1998;186(1):35–43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9457145>. Accessed June 20, 2014.
143. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. *Ann Intern Med.* 1993;119(1):23–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8498759>. Accessed June 20, 2014.
144. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. *JAMA.* 1999;281(11):1000–5. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10086434>. Accessed June 20, 2014.
145. Torrens M, Castillo C, Pérez-Solá V. Retention in a low-threshold methadone maintenance program. *Drug Alcohol Depend.* 1996;41(1):55–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8793310>. Accessed June 20, 2014.
146. Van Ameijden EJ, Langendam MW, Coutinho RA. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. *Addict Behav.* 1999;24(4):559–63. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10466851>. Accessed June 20, 2014.

147. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. *Drug Alcohol Depend.* 2003;72(1):59–65. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14563543>. Accessed June 20, 2014.
148. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. *N Engl J Med.* 1969;280(25):1372–5. doi:10.1056/NEJM196906192802502.
149. Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. *Drug Alcohol Depend.* 2008;94(1-3):199–206. doi:10.1016/j.drugalcdep.2007.11.021.
150. Gunne LM, Grönbladh L. The Swedish methadone maintenance program: a controlled study. *Drug Alcohol Depend.* 1981;7(3):249–56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7261900>. Accessed June 20, 2014.
151. Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. *Drug Alcohol Depend.* 2007;91(2-3):220–7. doi:10.1016/j.drugalcdep.2007.05.022.
152. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. *Lancet.* 1979;2(8141):485–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/90214>. Accessed June 20, 2014.
153. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. *Arch Gen Psychiatry.* 2006;63(1):102–9. doi:10.1001/archpsyc.63.1.102.
154. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. *JAMA.* 2000;283(10):1303–10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10714729>. Accessed June 20, 2014.
155. Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K. A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: implications for prevention of HIV. *Int J Addict.* 1991;26(12):1313–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1787024>. Accessed June 20, 2014.
156. Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadone maintenance clinic. *Am J Public Health.* 1991;81(9):1185–91. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1405649&tool=pmcentrez&rendertype=abstract>. Accessed June 20, 2014.
157. Bale RN, Van Stone WW, Kuldau JM, Engelsing TM, Elashoff RM, Zarcone VP. Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one-year follow-up. *Arch Gen Psychiatry.* 1980;37(2):179–93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7352849>. Accessed June 20, 2014.
158. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. *Addiction.* 2005;100(6):820–8. doi:10.1111/j.1360-0443.2005.01050.x.
159. Schwartz RP, Jaffe JH, Highfield DA, Callaman JM, O’Grady KE. A randomized controlled trial of interim methadone maintenance: 10-Month follow-up. *Drug Alcohol Depend.* 2007;86(1):30–6. doi:10.1016/j.drugalcdep.2006.04.017.
160. Ahmadi J. A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. *Drug Alcohol Depend.* 2002;66(2):111–4. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11906798>. Accessed June 20, 2014.
161. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. *J Subst Abuse Treat.* 2003;24(3):217–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12810142>. Accessed June 20, 2014.
162. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. *Eur J Clin Invest.* 2003;33(9):824–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12925043>. Accessed June 20, 2014.

163. Ahmadi J, Babaei-Beigi M, Alishahi M, Maany I, Hidari T. Twelve-month maintenance treatment of opium-dependent patients. *J Subst Abuse Treat*. 2004;26(1):363–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14698800>. Accessed June 20, 2014.
164. Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. *Addiction*. 1999;94(9):1337–47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10615719>. Accessed June 20, 2014.
165. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N Engl J Med*. 2003;349(10):949–58. doi:10.1056/NEJMoa022164.
166. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. *Drug Alcohol Depend*. 1995;40(1):17–25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8746920>. Accessed June 20, 2014.
167. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet*. 2003;361(9358):662–8. doi:10.1016/S0140-6736(03)12600-1.
168. Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. *Am J Psychiatry*. 2007;164(5):797–803. doi:10.1176/appi.ajp.164.5.797.
169. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. *Psychopharmacology (Berl)*. 1994;116(4):401–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7701040>. Accessed June 20, 2014.
170. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. *Am J Psychiatry*. 1994;151(7):1025–30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8010359>. Accessed June 20, 2014.
171. Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. *Int J Neuropsychopharmacol*. 2008;11(5):641–53. doi:10.1017/S146114570700836X.
172. Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;371(9631):2192–200. doi:10.1016/S0140-6736(08)60954-X.
173. Schottenfeld RS, Chawarski MC, Pakes JR, Pantaloni M V, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. *Am J Psychiatry*. 2005;162(2):340–9. doi:10.1176/appi.ajp.162.2.340.
174. Petitjean S, Stohler R, Déglon JJ, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. *Drug Alcohol Depend*. 2001;62(1):97–104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11173173>. Accessed June 20, 2014.
175. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. *Drug Alcohol Depend*. 2000;60(1):39–50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10821988>. Accessed June 20, 2014.
176. Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. *Arch Gen Psychiatry*. 1999;56(9):812–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12884887>. Accessed June 20, 2014.
177. Neri S, Bruno CM, Pulvirenti D, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. *Psychopharmacology (Berl)*. 2005;179(3):700–4. doi:10.1007/s00213-005-2239-x.
178. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. *Addiction*. 2003;98(4):441–52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12653814>. Accessed June 20, 2014.
179. Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. *Drug Alcohol Depend*. 2009;99(1-3):222–30. doi:10.1016/j.drugalcdep.2008.08.006.

180. Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. *Am J Addict.* 2004;13 Suppl 1:S29–41. doi:10.1080/10550490490440799.
181. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. *JAMA.* 2010;304(14):1576–83. doi:10.1001/jama.2010.1427.
182. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. *Addiction.* 1998;93(4):475–86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9684386>. Accessed June 20, 2014.
183. Krook AL, Brørs O, Dahlberg J, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. *Addiction.* 2002;97(5):533–42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12033654>. Accessed June 20, 2014.
184. Kristensen Ø, Espegren O, Asland R, Jakobsen E, Lie Ø, Seiler S. Buprenorphine and methadone to opiate addicts--a randomized trial. *Tidsskr den Nor lægeforening Tidsskr Prakt Med ny række.* 2005;125(2):148–51. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15665884>. Accessed June 20, 2014.
185. Maddux J, Prihoda T, Vogtsberger K. The relationship of methadone dose and other variables to outcomes of methadone maintenance. *Am J Addict.* 1997;6(3):246–255.
186. Kamien J, Branstetter S, Amass L. Buprenorphine-Naloxone Versus Methadone Maintenance Therapy: A Randomised Double-Blind With Opioid-Dependent Patients. *Heroin Addict Relat Clin Probl.* 2008;10(4):5–18.
187. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. *Arch Gen Psychiatry.* 1997;54(8):713–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9283506>. Accessed June 20, 2014.
188. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. *JAMA.* 1992;267(20):2750–5. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1578593>. Accessed June 20, 2014.
189. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. *J Nerv Ment Dis.* 1993;181(6):358–64. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8501457>. Accessed June 20, 2014.
190. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. *Arch Gen Psychiatry.* 1996;53(5):401–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8624183>. Accessed June 20, 2014.
191. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. *Cochrane database Syst Rev.* 2011;(4):CD001333. doi:10.1002/14651858.CD001333.pub4.
192. Stella L, D'Ambra C, Mazzeo F, et al. Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients. *Life Sci.* 2005;77(21):2717–22. doi:10.1016/j.lfs.2005.05.036.
193. Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. *Biol Psychiatry.* 1994;35(12):935–45. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8080893>. Accessed June 21, 2014.
194. San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. *Br J Addict.* 1991;86(8):983–90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1912753>. Accessed June 21, 2014.
195. Rawson RA, Glazer M, Callahan EJ, Liberman RP. Naltrexone and behavior therapy for heroin addiction. *NIDA Res Monogr.* 1979;(25):26–43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/117373>. Accessed June 21, 2014.
196. Lerner A, Sigal M, Bacalu A, Shiff R, Burganski I, Gelkopf M. A naltrexone double blind placebo controlled study in Israel. *Isr J Psychiatry Relat Sci.* 1992;29(1):36–43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1568861>. Accessed June 21, 2014.
197. Ladewig D. Naltrexone--an effective aid in the psychosocial rehabilitation process of former opiate dependent patients. *Ther Umsch.* 1990;47(3):247–50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2187266>. Accessed June 21, 2014.

198. Krupitsky EM, Zvartau EE, Masalov D V, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. *J Subst Abuse Treat.* 2006;31(4):319–28. doi:10.1016/j.jsat.2006.05.005.
199. Krupitsky EM, Zvartau EE, Masalov D V, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. *J Subst Abuse Treat.* 2004;26(4):285–94. doi:10.1016/j.jsat.2004.02.002.
200. Hollister L. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. *Arch Gen Psychiatry.* 1978;35(3):335–40. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/365122>. Accessed June 21, 2014.
201. Guo S, Jiang Z, Wu Y. Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification. *Hong Kong J Psychiatry.* 2001;11(4):2–8.
202. Curran S, Savage C. Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration. *NIDA Res Monogr.* 1976;(9):67–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/794722>. Accessed June 21, 2014.
203. Cornish JW, Metzger D, Woody GE, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. *J Subst Abuse Treat.* 1997;14(6):529–34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9437624>. Accessed June 21, 2014.
204. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. *Cochrane database Syst Rev.* 2011;(9):CD005031. doi:10.1002/14651858.CD005031.pub4.
205. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. *J Consult Clin Psychol.* 1997;65(5):803–10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9337499>. Accessed June 9, 2014.
206. Campbell BK, Fuller BE, Lee ES, et al. Facilitating outpatient treatment entry following detoxification for injection drug use: a multisite test of three interventions. *Psychol Addict Behav.* 2009;23(2):260–70. doi:10.1037/a0014205.
207. Hall S, Bass A, Hargreaves W, Loeb P. Contingency management and information feedback in outpatient heroin detoxification. *Behav Ther.* 1979;10(4):443–51.
208. Higgins ST, Stitzer ML, Bigelow GE, Liebson IA. Contingent methadone dose increases as a method for reducing illicit opiate use in detoxification patients. *NIDA Res Monogr.* 1984;55:178–84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6443376>. Accessed June 22, 2014.
209. Higgins ST, Stitzer ML, Bigelow GE, Liebson IA. Contingent methadone delivery: effects on illicit-opiate use. *Drug Alcohol Depend.* 1986;17(4):311–22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3757767>. Accessed June 22, 2014.
210. Katz EC, Chutuape MA, Jones H, Jasinski D, Fingerhood M, Stitzer M. Abstinence incentive effects in a short-term outpatient detoxification program. *Exp Clin Psychopharmacol.* 2004;12(4):262–8. doi:10.1037/1064-1297.12.4.262.
211. Katz EC, Brown BS, Schwartz RP, O’Grady KE, King SD, Gandhi D. Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction. *Drug Alcohol Depend.* 2011;117(1):24–30. doi:10.1016/j.drugalcdep.2010.12.024.
212. McCaul ME, Stitzer ML, Bigelow GE, Liebson IA. Contingency management interventions: effects on treatment outcome during methadone detoxification. *J Appl Behav Anal.* 1984;17(1):35–43. doi:10.1901/jaba.1984.17-35.
213. Rawson RA, Mann AJ, Tennant FS, Clabough D. Efficacy of psychotherapeutic counselling during 21-day ambulatory heroin detoxification. *NIDA Res Monogr.* 1983;43:310–4. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6410266>. Accessed June 22, 2014.
214. Robles E, Stitzer ML, Strain EC, Bigelow GE, Silverman K. Voucher-based reinforcement of opiate abstinence during methadone detoxification. *Drug Alcohol Depend.* 2002;65(2):179–89. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11772479>. Accessed June 22, 2014.
215. Yandoli D, Eisler I, Robbins C, Mulleady G, Dare C. A comparative study of family therapy in the treatment of opiate users in a London drug clinic. *J Fam Ther.* 2002;24(4):402–22.
216. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O’Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. *Neuropsychopharmacology.* 2005;30(1):205–11. doi:10.1038/sj.npp.1300600.

217. Elkashef A, Fudala PJ, Gorgon L, et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. *Drug Alcohol Depend.* 2006;85(3):191–7. doi:10.1016/j.drugalcdep.2006.04.010.
218. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. *J Clin Psychopharmacol.* 1997;17(6):485–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9408812>. Accessed June 22, 2014.
219. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. *Drug Alcohol Depend.* 2007;87(1):20–9. doi:10.1016/j.drugalcdep.2006.07.004.
220. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. *Exp Clin Psychopharmacol.* 2002;10(3):286–94. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12233989>. Accessed June 22, 2014.
221. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. *J Clin Psychopharmacol.* 2001;21(5):522–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11593078>. Accessed June 22, 2014.
222. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. *Neuropsychopharmacology.* 2004;29(5):969–81. doi:10.1038/sj.npp.1300392.
223. Mooney ME, Herin D V, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend.* 2009;101(1-2):34–41. doi:10.1016/j.drugalcdep.2008.10.016.
224. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. *Addiction.* 2003;98(8):1137–41. doi:10.1038/sj.npp.1300392.
225. Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. *Am J Drug Alcohol Abuse.* 1995;21(4):469–81. doi:10.3109/00952999509002711.
226. Margolin A, Avants S, Malison R, Kosten T. High- and low-dose mazindol for cocaine dependence in methadone-maintained patients: a preliminary evaluation. *Subst Abus.* 1997;18(3):125–31.
227. Perry EB, Gil R, Miles D, et al. Mazindol augmentation of antipsychotic treatment for schizophrenic patients with comorbid cocaine abuse or dependence: a preliminary double-blind, randomized, placebo-controlled trial. *J Dual Diagn.* 2005;1(1):37–47.
228. Stine SM, Krystal JH, Kosten TR, Charney DS. Mazindol treatment for cocaine dependence. *Drug Alcohol Depend.* 1995;39(3):245–52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8556974>. Accessed June 22, 2014.
229. Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. *Drug Alcohol Depend.* 1995;40(2):125–31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8745134>. Accessed June 22, 2014.
230. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. *Arch Gen Psychiatry.* 2006;63(2):219–28. doi:10.1001/archpsyc.63.2.219.
231. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. *J Addict Dis.* 2008;27(1):13–23. doi:10.1300/J069v27n01\_02.
232. Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. *Addiction.* 2000;95(2):219–28. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10723850>. Accessed June 22, 2014.
233. Grassi MC, Cioce AM, Giudici FD, Antonilli L, Nencini P. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. *Pharmacol Res.* 2007;55(2):117–21. doi:10.1016/j.phrs.2006.11.005.
234. George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. *Biol Psychiatry.*



- 2000;47(12):1080–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10862808>. Accessed June 22, 2014.
235. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. *Arch Gen Psychiatry*. 2004;61(3):264–72. doi:10.1001/archpsyc.61.3.264.
236. Carroll KM, Nich C, Ball SA, McCance E, Rounsaville BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. *Addiction*. 1998;93(5):713–27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9692270>. Accessed June 22, 2014.
237. Carroll K, Ziedonis D, O'Malley S, McCance-Katz E, Gordon L, Rounsaville B. Pharmacological interventions for alcohol- and cocaine-abusing individuals: A pilot study of disulfiram vs. naltrexone. *Am J Addict*. 1993;2(1):77–9.
238. Minozzi S, Amato L, Davoli M, et al. Anticonvulsants for cocaine dependence. *Cochrane database Syst Rev*. 2008;(2):CD006754. doi:10.1002/14651858.CD006754.pub2.
239. Berger SP, Winhusen TM, Somoza EC, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. *Addiction*. 2005;100 Suppl:58–67. doi:10.1111/j.1360-0443.2005.00983.x.
240. Bisaga A, Aharonovich E, Garawi F, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. *Drug Alcohol Depend*. 2006;81(3):267–74. doi:10.1016/j.drugalcdep.2005.07.009.
241. González G, Desai R, Sofuoglu M, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. *Drug Alcohol Depend*. 2007;87(1):1–9. doi:10.1016/j.drugalcdep.2006.07.003.
242. Campbell JL, Thomas HM, Gabrielli W, Liskow BI, Powell BJ. Impact of desipramine or carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. *J Addict Dis*. 1994;13(4):191–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7734469>. Accessed June 22, 2014.
243. Campbell J, Nickel EJ, Penick EC, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. *Am J Addict*. 2003;12(2):122–36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12746087>. Accessed May 27, 2014.
244. Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence. *Drug Alcohol Depend*. 1995;38(3):221–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7555622>. Accessed June 22, 2014.
245. Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. *Clin Pharmacol Ther*. 1997;62(1):89–105. doi:10.1016/S0009-9236(97)90155-7.
246. Kranzler HR, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. *Drug Alcohol Depend*. 1995;38(3):203–11. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7555620>. Accessed June 22, 2014.
247. Montoya ID, Levin FR, Fudala PJ, Gorelick DA. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. *Drug Alcohol Depend*. 1995;38(3):213–9. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2633654&tool=pmcentrez&rendertype=abstract>. Accessed June 4, 2014.
248. Crosby RD, Pearson VL, Eller C, Winegarden T, Graves NL. Phenytoin in the treatment of cocaine abuse: a double-blind study. *Clin Pharmacol Ther*. 1996;59(4):458–68. doi:10.1016/S0009-9236(96)90116-2.
249. Sofuoglu M, Pentel PR, Bliss RL, Goldman AI, Hatsukami DK. Effects of phenytoin on cocaine self-administration in humans. *Drug Alcohol Depend*. 1999;53(3):273–5. doi:10.1016/S0009-9236(96)90116-2.
250. Gonzalez G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. *Addiction*. 2003;98(11):1625–32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14616189>. Accessed June 22, 2014.
251. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. *Addiction*. 2005;100 Suppl:68–77. doi:10.1111/j.1360-0443.2005.00992.x.
252. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. *Drug Alcohol Depend*. 2004;75(3):233–40. doi:10.1016/j.drugalcdep.2004.03.008.

253. Giannini AJ, Billett W. Bromocriptine-desipramine protocol in treatment of cocaine addiction. *J Clin Pharmacol*. 1987;27(8):549–54. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3308977>. Accessed June 23, 2014.
254. Weddington WW, Brown BS, Haertzen CA, et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. *Am J Drug Alcohol Abuse*. 1991;17(2):137–52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1862788>. Accessed June 23, 2014.
255. Hall SM, Tunis S, Triffleman E, et al. Continuity of care and desipramine in primary cocaine abusers. *J Nerv Ment Dis*. 1994;182(10):570–5. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7931205>. Accessed June 23, 2014.
256. Kosten T, Oliveto A, Feingold A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. *Drug Alcohol Depend*. 2003;70(3):315–25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12757969>. Accessed June 23, 2014.
257. Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. *Arch Gen Psychiatry*. 1989;46(2):117–21. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2492422>. Accessed June 23, 2014.
258. McElroy SL, Weiss RD, Mendelson JH, Teoh SK, McAfee B, Mello NK. Desipramine treatment for relapse prevention in cocaine dependence. *NIDA Res Monogr*. 1989;95:57–63. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2701323>. Accessed June 23, 2014.
259. Arndt IO, Dorozynsky L, Woody GE, McLellan AT, O'Brien CP. Desipramine treatment of cocaine dependence in methadone-maintained patients. *Arch Gen Psychiatry*. 1992;49(11):888–93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1444727>. Accessed June 23, 2014.
260. McDowell D, Nunes E V, Seracini AM, et al. Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. *Drug Alcohol Depend*. 2005;80(2):209–21. doi:10.1016/j.drugalcdep.2005.03.026.
261. Tennant FS, Tarver AL. Double-blind comparison of desipramine and placebo in withdrawal from cocaine dependence. *NIDA Res Monogr*. 1984;55:159–63. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6443373>. Accessed June 23, 2014.
262. O'Brien CP, Childress AR, Arndt IO, McLellan AT, Woody GE, Maany I. Pharmacological and behavioral treatments of cocaine dependence: controlled studies. *J Clin Psychiatry*. 1988;49 Suppl:17–22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3276670>. Accessed June 23, 2014.
263. Kosten TR, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. *Arch Gen Psychiatry*. 1992;49(11):894–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1444728>. Accessed June 23, 2014.
264. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. *Arch Gen Psychiatry*. 1994;51(3):177–87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8122955>. Accessed March 14, 2014.
265. Giannini AJ, Loiselle RH, Giannini MC. Space-based abstinence: alleviation of withdrawal symptoms in combinative cocaine-phencyclidine abuse. *J Toxicol Clin Toxicol*. 1987;25(6):493–500. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3441016>. Accessed June 23, 2014.
266. Kolar AF, Brown BS, Weddington WW, Haertzen CC, Michaelson BS, Jaffe JH. Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine. *Int J Addict*. 1992;27(7):849–68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1319961>. Accessed June 23, 2014.
267. Giannini AJ, Malone DA, Giannini MC, Price WA, Loiselle RH. Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine. *J Clin Pharmacol*. 1986;26(3):211–4. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3514688>. Accessed June 23, 2014.
268. Batki SL, Washburn AM, Delucchi K, Jones RT. A controlled trial of fluoxetine in crack cocaine dependence. *Drug Alcohol Depend*. 1996;41(2):137–42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8809502>. Accessed June 23, 2014.
269. Winstanley EL, Bigelow GE, Silverman K, Johnson RE, Strain EC. A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. *J Subst Abuse Treat*. 2011;40(3):255–64. doi:10.1016/j.jsat.2010.11.010.

270. Covi L, Hess JM, Kreiter NA, Haertzen CA. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. *Am J Drug Alcohol Abuse*. 1995;21(3):327–44. doi:10.3109/00952999509002701.
271. Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. *J Clin Psychopharmacol*. 1995;15(3):163–74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7635993>. Accessed June 16, 2014.
272. Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. *Drug Alcohol Depend*. 2001;63(3):207–14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11418225>. Accessed May 28, 2014.
273. Passos SRL, Camacho LAB, Lopes CS, dos Santos MAB. Nefazodone in out-patient treatment of inhaled cocaine dependence: a randomized double-blind placebo-controlled trial. *Addiction*. 2005;100(4):489–94. doi:10.1111/j.1360-0443.2005.01041.x.
274. Ciraulo DA, Knapp C, Rotrosen J, et al. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. *Addiction*. 2005;100 Suppl:23–31. doi:10.1111/j.1360-0443.2005.00984.x.
275. Ciraulo DA, Sarid-Segal O, Knapp CM, et al. Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. *Addiction*. 2005;100 Suppl(Suppl 1):12–22. doi:10.1111/j.1360-0443.2005.00985.x.
276. Cornish JW, Maany I, Fudala PJ, Ehrman RN, Robbins SJ, O'Brien CP. A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. *Drug Alcohol Depend*. 2001;61(2):183–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11137283>. Accessed June 23, 2014.
277. Johnson BA, Chen YR, Swann AC, et al. Ritanserin in the treatment of cocaine dependence. *Biol Psychiatry*. 1997;42(10):932–40. doi:10.1016/S0006-3223(96)00490-8.
278. Giannini AJ, Loiselle RH, Graham BH, Folts DJ. Behavioral response to buspirone in cocaine and phencyclidine withdrawal. *J Subst Abuse Treat*. 1993;10(6):523–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8308936>. Accessed June 23, 2014.
279. Jenkins SW, Warfield NA, Blaine JD, et al. A pilot trial of gepirone vs. placebo in the treatment of cocaine dependency. *Psychopharmacol Bull*. 1992;28(1):21–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1609038>. Accessed June 23, 2014.
280. Jones HE, Johnson RE, Bigelow GE, Silverman K, Mudric T, Strain EC. Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial. *Am J Addict*. 2004;13(5):421–37. doi:10.1080/10550490490512753.
281. Moeller FG, Schmitz JM, Steinberg JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. *Am J Drug Alcohol Abuse*. 2007;33(3):367–78. doi:10.1080/00952990701313686.
282. Amato L, Minozzi S, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. *Cochrane database Syst Rev*. 2011;(12):CD003352. doi:10.1002/14651858.CD003352.pub3.
283. Shoptaw S, Watson DW, Reiber C, et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). *Addiction*. 2005;100 Suppl:78–90. doi:10.1111/j.1360-0443.2005.00991.x.
284. Schmitz JM, Lindsay JA, Stotts AL, Green CE, Moeller FG. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. *Exp Clin Psychopharmacol*. 2010;18(3):238–44. doi:10.1037/a0019195.
285. Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. *Drug Alcohol Depend*. 2007;88(2-3):214–23. doi:10.1016/j.drugalcdep.2006.10.011.
286. Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. *Drug Alcohol Depend*. 2008;94(1-3):142–50. doi:10.1016/j.drugalcdep.2007.11.004.
287. Kampman KM, Dackis C, Lynch KG, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. *Drug Alcohol Depend*. 2006;85(2):129–37. doi:10.1016/j.drugalcdep.2006.04.002.

288. Shoptaw S, Kintaudi PC, Charuvastra C, Ling W. A screening trial of amantadine as a medication for cocaine dependence. *Drug Alcohol Depend.* 2002;66(3):217–24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12062456>. Accessed June 23, 2014.
289. Handelsman L, Limpitlaw L, Williams D, Schmeidler J, Paris P, Stimmel B. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. *Drug Alcohol Depend.* 1995;39(3):173–80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8556965>. Accessed June 23, 2014.
290. Alterman AI, Droba M, Antelo RE, et al. Amantadine may facilitate detoxification of cocaine addicts. *Drug Alcohol Depend.* 1992;31(1):19–29. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1330470>. Accessed June 23, 2014.
291. Giannini AJ, Folts DJ, Feather JN, Sullivan BS. Bromocriptine and amantadine in cocaine detoxification. *Psychiatry Res.* 1989;29(1):11–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2672061>. Accessed June 23, 2014.
292. Oliveto A, Kosten TR, Schottenfeld R, Falcioni J, Ziedonis D. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. *J Subst Abuse Treat.* 1995;12(6):423–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8749726>. Accessed June 23, 2014.
293. Pérez de los Cobos J, Duro P, Trujols J, et al. Methadone tapering plus amantadine to detoxify heroin-dependent inpatients with or without an active cocaine use disorder: two randomised controlled trials. *Drug Alcohol Depend.* 2001;63(2):187–95. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11376923>. Accessed June 23, 2014.
294. Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. *Cochrane database Syst Rev.* 2007;(3):CD006306. doi:10.1002/14651858.CD006306.pub2.
295. Berger SP, Hall S, Mickalian JD, et al. Haloperidol antagonism of cue-elicited cocaine craving. *Lancet.* 1996;347(9000):504–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8596268>. Accessed June 23, 2014.
296. Smelson DA, Williams J, Ziedonis D, et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. *J Subst Abuse Treat.* 2004;27(1):45–9. doi:10.1016/j.jsat.2004.03.009.
297. Kampman KM, Pettinati H, Lynch KG, Sparkman T, O’Brien CP. A pilot trial of olanzapine for the treatment of cocaine dependence. *Drug Alcohol Depend.* 2003;70(3):265–73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12757964>. Accessed June 23, 2014.
298. Reid MS, Casadonte P, Baker S, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. *Addiction.* 2005;100 Suppl:43–57. doi:10.1111/j.1360-0443.2005.00990.x.
299. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. *J Clin Psychopharmacol.* 2006;26(1):9–12. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16415698>. Accessed June 23, 2014.
300. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes E V. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend.* 2011;116(1-3):142–50. doi:10.1016/j.drugalcdep.2010.12.010.
301. Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. *Am J Addict.* 2004;13(1):21–32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14766435>. Accessed March 16, 2014.
302. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. *Am J Addict.* 2009;18(1):53–64. doi:10.1080/10550490802408936.
303. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. *J Psychopharmacol.* 2009;23(1):84–93. doi:10.1177/0269881108089584.
304. Tirado CF, Goldman M, Lynch K, Kampman KM, O’Brien CP. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. *Drug Alcohol Depend.* 2008;94(1-3):254–7. doi:10.1016/j.drugalcdep.2007.10.020.
305. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. *Am J Addict.* 2010;19(6):481–9. doi:10.1111/j.1521-0391.2010.00076.x.

306. McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. *Drug Alcohol Depend.* 2009;105(1-2):132–8. doi:10.1016/j.drugalcdep.2009.06.022.
307. Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. *Am J Addict.* 2010;19(2):187–9. doi:10.1111/j.1521-0391.2009.00027.x.
308. Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. *Addict Behav.* 2005;30(9):1824–33. doi:10.1016/j.addbeh.2005.07.007.